Scientific Posters

ARV-based prevention: Vertical transmission and PEP	
P001	**Near-elimination of vertical HIV transmission in England: successes and remaining challenges, 2014–2023** Helen Peters, Kate Francis, Claire Thorne, on behalf of NHS England's Infectious Diseases in Pregnancy HIV Clinical Expert Review Panel (London, UK)
P002	**Characteristics and outcomes of infants born to women living with HIV in England receiving three-drug postnatal prophylaxis, 2020–2025** Helen Peters, Kate Francis, Rebecca Sconza, Charlie Gorman, Charlotte Roberts, Alasdair Bamford, Claire Thorne (London, UK)
P003	**Real-world safety, tolerability and treatment completion of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as post-exposure prophylaxis in a large STI clinic** Flavia Passini, Nicolò Capra, Riccardo Lolatto, Angelo Roberto Raccagni, Tommaso Clemente, Elena Bruzzesi, Anna Danise, Gaia Catalano, Davide Beretta, Paola Rienzo, Federico Furlan, Antonella Castagna, Silvia Nozza (Milan, Italy)
P004	**Referral from post-exposure prophylaxis to pre-exposure prophylaxis in the US, 2016–2025: an analysis of real-world claims data** Kenneth Mayer, Travis Lim, Yi-Han Hu, Wenyi Wang, Laura Mann, Jason Hindman, Lillian Brown (Boston, MA, USA)
P005	**Dual antiretroviral therapy in pregnant women living with HIV in Belgium** Marie Aractingi, Christine Gilles, Severine Caluwaerts, Sophie Henrard, Marc Delforge, Charlotte Martin, Deborah Konopnicki (Brussels, Belgium)
P006	**Exploration of surgical procedures with the highest risk for potential HIV transmission** David Custers, Jessica van der Mannen, Kees Brinkman, on behalf of HIV team OLVG, Amsterdam (Amsterdam, Netherlands)
P007	**Enhancing nPEP adherence and mental health via a LINE-based digital intervention: a randomized controlled trial, a first 52-weeks result** Jen-Chung Chu, Shu-Yuan Li, Che-Yu Kuo (Taoyuan City, Taiwan)
P008	**Vertical transmission of HIV among ART-treated HIV-positive pregnant women in Burundi: a multi-site cohort study across 12 clinics** Emmanuel Nkengurutse, Nadine Uwimana, Desire Ramadhan (Bujumbura, Burundi)
ARV-based Prevention: PrEP	
P009	**High persistence, adherence and tolerability of long-acting cabotegravir for HIV pre-exposure prophylaxis: national implementation experience from the Italian PrIDE cohort** Davide Moschese, Gianluca Frate, Damiano Farinacci, Chiara Fusetti, Angelo Roberto Raccagni, Francesco Barbaro, Nicholas Brian Bana, Virginia Barchi, Valentina Sala, Leonardo Del Negro, Enrico Caruso, Samuel Lazzarin, Gabriele Loi, Antonella Castagna, Andrea Gori, Andrea Antinori, Silvia Nozza, Valentina Mazzotta (Milan, Italy)
P010	**Early multicompartment distribution of long-acting cabotegravir after the first intramuscular injection for HIV pre-exposure prophylaxis: preliminary results from the TUTT*E study** Massimo Tempestilli, Davide Moschese, Damiano Farinacci, Sara Soloperto, Maria Maddalena Plazzi, Simona Gili, Samuel Lazzarin, Virginia Barchi, Elisa Martina, Francesco Caruso, Rebecca Jo Steiner, Eleonora Cimini, Andrea Gori, Andrea Antinori, Antonio D'Avolio, Valentina Mazzotta (Rome, Italy)

Scientific Posters

ARV-based prevention: PrEP (continued)

P011	**Potential target populations for lenacapavir PrEP in Italy: a real-world analysis from the PrIDE cohort (Epi-PrEP Study)** Valentina Mazzotta, Gianluca Frate, Anna Lucchini, Chiara Fusetti, Giulia Micheli, Vito Leonardo Del Negro, Giulia C Marchetti, Anna M Cattelan, Roberto Caldera, Gabriele Forcina, Massimo Cernuschi, Antonella Castagna, Silvia Nozza, Davide Moschese, Andrea Antinori, on behalf of PrIDE/Epi-PrEP Study Group (Rome, Italy)
P012	**Phenotypic analyses of HIV clinical isolates with capsid substitutions observed in the PURPOSE 1 and PURPOSE 2 studies** Matthew R Hendricks, Kristen Andreatta, Jiani Li, Christoph C Carter, Christian Callebaut, Stephanie Cox (Foster City, CA, US)
P013	**Uptake, adherence and effectiveness over four years of cabotegravir long-acting pre-exposure prophylaxis in the US OPERA cohort** Ricky Hsu, Laurence Brunet, Anthony Mills, Kevin Frost, Gerald Pierone, Michael Sension, Philip Lackey, Karam Mounzer, Michael Wohlfeiler, Jennifer Fusco, Todd McKeon, Piotr Budnik, Adrienne Guignard, Vani Vannappagari, Gregory Fusco (Vero Beach, FL, US)
P014	**Injection-site reactions drive early discontinuation of lenacapavir for HIV PrEP in real-world clinical practice** Joseph Cherabie, Tommy Schafer, Andrew Crone, Aniruddha Hazra (Chicago, IL, US)
P015	**EXPrESSIVE-11: a phase 3 study evaluating MK-8527 oral once monthly for HIV pre-exposure prophylaxis in cisgender men who have sex with men, transgender women, transgender men and gender nonbinary individuals who are at greater likelihood of HIV exposure** Raphael J Landovitz, Susan Buchbinder, David V Glidden, Beatriz Grinsztejn, Jean-Michel Molina, Fredrick O Otieno, Nittaya Phanuphak, Adrienne E Shapiro, Dawn Averitt, Jean Marie Arduino, Lina de Montigny, Jemar Bather, Peggy May Tan Hwang, Barbara Evans, Luisa M Stamm, Christopher J Bruno, Rebeca M Plank (Rahway, NJ, US)
P016	**Pre-exposure prophylaxis with cabotegravir long-acting versus daily oral tablets: increased frequency of testing for HIV and sexually transmitted infections** Gerald Pierone Jr, Rachel Palmieri Weber, Laurence Brunet, Anthony Mills, Michael Sension, Philip Lackey, Michael Wohlfeiler, Jennifer Fusco, Supriya Sarakar, Vani Vannappagari, Kimberley Brown, Gregory Fusco (Vero Beach, FL, US)
P017	**EXPrESSIVE-10: a phase 3 study evaluating MK-8527 oral once monthly for HIV pre-exposure prophylaxis in cisgender women who are at greater likelihood of HIV exposure** Renee Heffron, Connie L Celum, Linda-Gail Bekker, Elizabeth A Bukusi, Sinead Delany-Moretlwe, Deborah Donnell, Flavia Matovu Kiweewa, Nelly Mugo, Andrew Mujugira, Simon Odiwuor Ondiek, Nandisile Sikwana, Elizabeth S Russell, Patricia Castronuovo, Yash Kapoor, John Love, Anjana Grandhi, Luisa M Stamm, Cyrus Badshah, Rebeca M Plank (Birmingham, AL, US)
P018	**Abstract withdrawn**
P019	**Impact of follow-up frequency on STI detection and prevention among men who have sex with men (MSM) and women using HIV PrEP: a decision-analytic model** Eduard Vidal-Barraquer, Natalya Danchenko, Sarah-Jane Anderson, Mairi Ward, Ashley Davis, Heidi Swygard, Aimee A Metzner, Barry S Zingman, Kevin Hatfield, Brittany Marie Williams, Nasser Mohammed, Claire Dewsnap, Juddy Otti, Jenny Scherzer, Laure Dupont Benjamin, Jonathan Tosh, Sean Robbins, Jean Andre Van Wyk (London, UK)

Scientific Posters

ARV-based prevention: PrEP (continued)

P020	**Willing but unable: how intersecting vulnerabilities and structural barriers fracture the PrEP cascade among migrants in Europe** Haoyi Wang, Hala Majdoub, Anne Flaherty-Gupta, Kim Isip, Pedro Barrios Sanchez, Francesco Bellissimo, Yiannis Charilaou, Christos Krasidis, Rosaline M'Bayo, Stephen Amoah, Trésors Kouadio, Robert Ian Kibet Ouko Babu, Ann Piercy, Abimbola Ajomale, Moro Yapha, Etinosa Erevbenagie-Johnbull, Letonde Hermine Gbedo, Kai Jonas, Hanne Zimmermann, Denis Onyango (Maastricht, Netherlands)
P021	**Impact of doxycycline post-exposure prophylaxis (doxy-PEP) implementation on reducing syphilis incidence among HIV PrEP users: a real-world experience at Taoyuan General Hospital, Taiwan** Jen-Chung Chu, Che-Yu Kuo (Taoyuan City, Taiwan)
P022	**Estimating unmet need for PrEP in France using national claims data and machine learning** Marc Tassi, Lauren Inchboard, Martin Siguier, Marine Vierling, Sophie Larrieu, Sparkle Russell-Puleri, Claire Idelovici-Marchal, Elias Benabadji, Romain Palich, Olivier Robineau (Puteaux, France)
P023	**Relationships of pre-exposure prophylaxis (PrEP) side effect concerns and modality preference among American gay, bisexual and other men who have sex with men (GBMSM)** Katie B Biello, Iju Shakya, Ronnie M Gravett, Jean Marie Arduino, Katia J Bruxvoort, Yohance Whiteside, Megan E McCabe, Valerie Raziano, Kenneth H Mayer (Providence, RI, USA)
P024	**HIV-1 molecular characteristics and transmitted drug resistance mutations epidemiology affecting pre-exposure prophylaxis in the HIV-1 A6 epidemic in Poland – a cross-sectional study** Andrzej Załęski, Agnieszka Lembas, Tomasz Dyda, Justyna Orzechowska, Aldona Kot, Joanna Osińska, Justyna Stempkowska-Rejek, Marcin Dręczewski, Marta Dobrzyńska, Michał Dowiatt, Alicja Wiercińska-Drapało (Warsaw, Poland)
P025	**Adherence to European standards of HIV prevention and care of pre-exposure prophylaxis (PrEP) in Italy: results from the PrIDE cohort** Giulia Micheli, Gianluca Frate, Sara Leone, Enrico Caruso, Angelo Roberto Raccagni, Marco Tutone, Daniele Tesoro, Vito Leonardo Del Negro, Anna Lucchini, Andrea Santoro, Andrea Antinori, Davide Moschese, Silvia Nozza, Massimo Cernuschi, Valentina Mazzotta (Rome, Italy)
P026	**Factors associated with hepatitis B (HBV) status and HIV pre-exposure prophylaxis (PrEP) use among gay, bisexual and other men who have sex with men (GBM) in Vancouver, Toronto and Montreal, Canada** Mark Hull, Aki Gormezano, Lu Wang, Darrell Tan, Nathan Lachowsky, Daniel Grace, Jason Trigg, Justin Barath, Alan Lal, Joseph Cox, David Moore (British Columbia, Canada)
P027	**Injectable cabotegravir for HIV PrEP: early real-world NHS implementation in a North West England sexual health service** Martyn Wood, Emily Clarke, Sarah Keegan, Mark Lawton (Liverpool, UK)
P028	**Real-world barriers to PrEP access and HIV knowledge among first-time PrEP users in Portugal: the POSITIVE CARE study** Raquel Borges de Pinho, Inês Maury, Patrícia Pacheco, Kamal Mansinho, Ana Cláudia Miranda, Cláudia Franco, Cátia Caldas, Fernando Maltez, Maria José Manata, Josefina Mendez, Laura Paixão (Paço de Arcos, Portugal)
P029	**Abstract withdrawn**
P030	**Key stakeholder perspectives on the barriers and facilitators for HIV prevention services among people experiencing homelessness** Erica Pool, Alison Rodger, Shema Tariq, Andrew Hayward, Charles Witzel (London, UK)
P031	**Abstract withdrawn**

Scientific Posters

ARV-based prevention: PrEP (continued)

P032	**Regional reimbursement of STI screening and PrEP initiation in Italy: an ecological analysis from the PrIDE cohort (Epi-PrEP study)** Sara Leone, Davide Moschese, Gianluca Frate, Enrico Caruso, Angelo Roberto Raccagni, Samuel Lazzarin, Anna Lucchini, Giulia C Marchetti, Anna M Cattelan, Salvio Cecere, Vito Leonardo Del Negro, Marianna Menozzi, Roberto Caldera, Gabriele Forcina, Andrea Antinori, Silvia Nozza, Massimo Cernuschi, Valentina Mazzotta, on behalf of PrIDE/Epi-PrEP Study Group (Rome, Italy)
P033	**Factors associated with early losses along the PrEP care cascade following referral to a hospital-based PrEP unit** Lucio Jesus García Fraile Fraile, Inmaculada Jarrín Vera, Violeta Sampériz Rubio, Ángela Gutiérrez Liarte, Marta de Miguel Montero, María López Cabanillas, Ignacio de los Santos Gil (Madrid, Spain)
P034	**Poke or pill? Real-world adherence, persistence and discontinuation data from the first year of introducing injectable PrEP at a Toronto community sexual health clinic** Kevin Woodward, Tim Guimond, Hommood Alrowais, Victor Monroy, Lucas Gergyek (Toronto, Canada)
P035	**Beyond the pill: first-year real-world outcomes of injectable PrEP at a Toronto community sexual health clinic** Kevin Woodward, Tim Guimond, Hommood Alrowais, Victor Monroy, Lucas Gergyek (Toronto, Canada)
P036	**Barriers to PrEP access among underserved groups in the UK: a co-produced critical interpretive synthesis** Elizabeth Eithne McKeand, Sara Paparini, Vian Rajabzadeh, Sophie Strachan, Melanie Smuk, Laura Leigh Vetters, Nishat Halim, Caro Camargo, Chloé Pasin, Anqa Awan, Taranjit Chana, Kelsea Delatango, Vimbai Mandaza, Pamela Menzies-Banton, Zoch Nwaosu, Juddy Otti, Kyle Ring, Chloe Orkin, Megan Devonald, PrEP-Position Steering Group Member, on behalf of PrEP-Position Steering Group (London, UK)
P037	**Pre-exposure prophylaxis in men who have sex with men and new HIV infections in Croatia** Šime Zekan, Vanja Romih Pintar, Marija Santini, Josip Begovac (Zagreb, Croatia)

Treatment strategies: Novel therapeutic targets (phase I and II)

P038	**Once-weekly ulonivirine provides a week of forgiveness after a missed dose** Michelle M Pham, Jingcheng Xiao, Shuang Xu, Uche Okoro, Yayun Xu, Sandy Rawlins, Mengchun Li, Bill Poland, Vincent Dubois, Ryan C Vargo, Randolph P Matthews (Rahway, NJ, USA)
P039	**Phase 1 results for the selection of a new long-acting rilpivirine formulation to support dosing three times a year** Eileen Castronova, Ronald D'Amico, Jörg Sievers, Randa Hareedy, Gilda Bontempo, Lisa Morgan, Shawn L Searle, Katherine Sides, Jeremy Roberts, Herta Crauwels, Kati Vandermeulen, Lorant Leopold, Eileen Birmingham, Rodica Van Solingen-Ristea, Jon Collins, Lionel Tan (Durham, NC, USA)
P040	**Single-dose escalation study of TMB-365 in people living with HIV: safety, pharmacokinetics and antiviral activity** Edwin DeJesus, Jacob P Lalezari, Moti Ramgopal, Javier Morales, Leandro Mena, Kuei-Ling Kuo, Ying-An Lai, Martin Markowitz (Irvine, CA, USA)
P041	**Safety, tolerability and acceptability of HIV-1 capsid inhibitor VH4011499 injectable formulation** Bronagh Shepherd, Veronica Bainbridge, Jose R Castillo-Mancilla, Nilay Thakkar, Gilda Bontempo, Adelaide Jewell, Jia Chang, Shawn L Searle, Noopur Singh, Lisa Morgan, Babafemi Taiwo, Paul Benn (Durham, NC, US)
P042	**Antiviral activity, pharmacokinetics and safety of oral GS-3242 for HIV-1 treatment** Samir Gupta, Mezgebe Berhe, Anchalee Avihingsanon, Nan Zhang, Aobo Wang, Kristen Andreatta, Ramya Rao, Kwad Mponponsuo, Peter Sklar, Gary Sinclair (Foster City, CA, USA)

Scientific Posters

Treatment strategies: Novel therapeutic targets (phase I and II) (continued)	
P043	**The evolution of integrase strand transfer inhibitors: VH-184, a 3rd-generation inhibitor with an enhanced resistance profile** Jerry Jeffrey, Jon Collins, Luise Rogg, Joseph Horton, Sherene Min, Cynthia Donovan, Turner Overton, Jorge Villacian (Durham, NC, USA)
P044	**Therapeutic development of novel proteolysis-targeting chimeras for degradation of HIV-1 integrase** Faisal Abedin, Xianyou Peng, Madhusoodanan Mottamal, Olaf Kutsch, Guangdi Wang, Thomas Huckaba (New Orleans, LA, USA)
P045	**Switching from standard-of-care antiretroviral therapy (SoC ART) to dual therapy lotivibart (LVB) plus cabotegravir (CAB) is associated with a modest reduction in chronic innate immune activation in virologically suppressed adults with HIV** Michael Keegan, Xiaowen Chen, Wilson Chen, Kumar Chandan, Peter Leone, Jan Losos, Richard Dunham (London, UK)
P046	**Positive experiences of healthcare staff with administration of twice-yearly intravenous lotivibart for HIV-1 treatment in the EMBRACE study** Cassidy A Gutner, Irina Kolobova, Peter Leone, Riccardo D'Agostino, Michael Warwick-Sanders, Viviana Wilches, Owen Cooper, Jack Brouwer, Jennifer N Hill, Jan Losos (Durham, NC, USA)
P047	**Chidamide synergizes with NKG2D CAR-NK cells to clear HIV latency by upregulating ligand expression** Biao Zhu, Zhikai Wan, Xiaotang Zhou, Xueling Zhu, Bohao Dai (Zhejiang, China)
Treatment Strategies: RCTS: oral and injectable therapy in first-line and suppressed switch populations	
P048	**Bictegravir/lenacapavir: baseline and week 48 resistance in the ARTISTRY-2 trial** Michelle L D'Antoni, Kristen Andreatta, Cameron Soulette, Priyanka Arora, Eric Meissner, Kwad Mponponsuo, Peter Sklar, Nicolas Margot, Christian Callebaut (Foster City, CA, USA)
P049	**Efficacy and safety of once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily standard of care (SOC) across demographic and clinical subgroups through week 48 in the phase 3 ISLEND-2 trial** Miłosz Parczewski, Patricia Echeverria, Luis Fernando López Cortés, Georg Behrens, Anchalee Avihingsanon, Alexandra Calmy, Julie Fox, Marcelo H Losso, Bartosz Szetela, María de Lagarde, Olayemi Osiyemi, Joel Gallant, Richard Kaplan, Thomas B Campbell, Hongyuan Wang, Ke Chen, Fadi Shihadeh, Tracy L Diamond, Elena Bekerman, Hadas Dvory-Sobol, Cyril Llamoso, Devi SenGupta, Amy E Colson, on behalf of ISLEND-2 Study Team (Szczecin, Poland)
P050	**Once-weekly oral islatravir/lenacapavir (ISL/LEN) versus daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with HIV-1: week 48 subgroup analyses of the phase 3 ISLEND-1 trial** Jürgen K Rockstroh, Anthony Mills, Benoit Trottier, Shawn Hassler, Manoj Dalmia, Bertrand Lebouché, Cynthia Gay, Alvaro Mena de Cea, Clara Lehmann, Hartmut Stocker, Javier Morales-Ramirez, Michael Sension, Marta Boffito, Michinori Shirano, Shan-Yu Liu, Ke Chen, Fadi Shihadeh, Jason Kim, Renee-Claude Mercier, Hadas Dvory-Sobol, Cyril Llamoso, Devi SenGupta, Chloe Orkin, on behalf of ISLEND-1 Study Team (London, UK)
P051	**VOGUE: consistent efficacy of DTG/3TC versus BIC/FTC/TAF across clinically relevant subgroups in adults initiating ART** Maria de Lagarde Sebastián, Marcelo D Martins, Dai Watanabe, Kehui Wang, Richard Grove, Ruolan Wang, Adelaide Jewell, Emilie Elliot, Rebecca Borsi, Parul Patel, Michelle Kisare, Piotr Budnik, Jean van Wyk (Madrid, Spain)

Scientific Posters

Treatment Strategies: RCTS: oral and injectable therapy in first-line and suppressed switch populations (continued)

P052	**Longitudinal dynamics of viraemic events: a multi-state modelling analysis of dolutegravir/lamivudine versus 3-drug regimens** Richard Grove, Pedro Cahn, Josep M Llibre, Avishek Chatterjee, Lijina Kaiprath, Gustavo Verdier, Piotr Budnik, Michelle Kisare (London, UK)
P053	**Comparable efficacy of dolutegravir/lamivudine versus second-generation integrase strand transfer inhibitor-based 3-drug regimens across the baseline viral load continuum: a participant-level meta-analysis** Pedro Cahn, Carlos Brites, Ezequiel Córdova, Maria Ines Figueroa, Jade Ghosn, Belinda Ha, Lijina Kaiprath, Richard Grove, Muhammed Murshid VR, Jamile Ballivian, Michelle Kisare, Gustavo Verdier, Piotr Budnik, Parul Patel (Buenos Aires, Argentina)
P054	**Efficacy of doravirine plus dolutegravir dual therapy in people with HIV RNA below 50 copies/mL: a randomised open-label study (DORDOL)** Jesal Gohil, Sarah Pett, Alan Winston, Andrew Hill, Roya Movahedi, Darwin Matila, Ebunoluwa Taiwo, Deirdre Sally, Merle Henderson, Bryony Simmons, Kaitlyn McCann, Manisha Joshi, Andrea Calcagno, Marta Boffito (London, UK)
P055	**Efficacy and safety of early switch to dolutegravir/lamivudine from integrase inhibitors-based 3-drug regimens in HIV-1-infected adults: 48-week results of the EDOLAS randomised trial** Roberta Gagliardini, Alessandro Cozzi-Lepri, Laura Comi, Lucia Taramasso, Maria Maddalena Plazzi, Sandrine Ottou, Giuseppe Lapadula, Silvia Nozza, Annamaria Cattelan, Massimiliano Fabbiani, Giulia Marchetti, Maria Vittoria Cossu, Alessandro Bartoloni, Marianna Menozzi, Carlo Torti, Federico De Zottis, Rita Bellagamba, Jessica Paulicelli, Diego Ripamonti, Paolo Bonfanti, Antonio Di Biagio, Valentina Mazzotta, Antonella Castagna, Andrea Gori, Cristina Mussini, Franco Maggiolo, Andrea Antinori, on behalf of EDOLAS Study Group (Rome, Italy)
P056	**Understanding treatment experiences with weekly oral islatravir/lenacapavir in the phase 3 ISLEND-2 study: participant and provider interviews** Chloe M Orkin, Peter J Ruane, Ploenchan Chetchotisakd, Winai Ratanasuwan, Mark O'Reilly, Ronald Nahass, Maria Lagarde, Patricia Echeverria, Frank Post, Alejandro Areans-Pinto, David Baker, Ei Kinai, Hideta Nakmura, Amy Colson, Melissa Shaugnessy, Keith Dunn, James Jarrett, Ke Chen, Arman Papadakis Sali, Devi SenGupta, Cyril Llamoso, Hadas Dvory-Sobol, Onyema Ogbuagu, William You, Claire Graziani-Taugeron (London, UK)
P057	**Quality of life and treatment preference with weekly ISL/LEN versus standard of care: week 48 patient-reported outcome analysis of the phase 3 ISLEND-2 study** Moti Ramgopal, Peter J Ruane, Ploenchan Chetchotisakd, Winai Ratanasuwan, Afaaf Liberty, Princy Kumar, Ronald G Nahass, Mark O'Reilly, Charlotte-Paige Rolle, William J Towner, Patricia Echeverria, Maria Lagarde, Alejandro Arenas-Pinto, Frank Post, Georg Behrens, Isabel Lidia Cassetti, Alexandra Calmy, Hideta Nakamura, Amy Colson, Hongyuan Wang, Hadas Dvory-Sobol, Cyril Llamoso, Devi SenGupta, Yohance Whiteside, James Jarrett, Todd L Saretsky, Arman P Sali, Miłosz Parczewski (Szczecin, Poland)
P058	**Efficacy of long-acting cabotegravir plus rilpivirine immediately post-suppression on DTG/3TC in prior high viraemic, low CD4 HIV-1 subgroups: 11-month VOLITION results** Chinyere Okoli, Patricia de Los Rios, Charlotte-Paige Rolle, Paul Benson, Pedro Cahn, Teresa Aldamiz-Echevarria, Joaquin Bravo Urbieta, Andrea Antinori, Rosario Palacios Muñoz, Kai Hove, Richard Grove, Avishek Chatterjee, Kehui Wang, Samia Dakhia (London, UK)
P059	**Virological outcomes after late CAB+RPV LA injections in newly suppressed people with HIV-1: 11-month results from the VOLITION study** Chinyere Okoli, Patricia de los Rios, Charlotte-Paige Rolle, Laurence Slama, Andrea Antinori, Guillermo Cuevas Tascon, Jose Rafael Granados Monzon, Michele Hernandez Cabrera, Celia Jonsson-Oldenbüttel, Kai Hove, Richard Grove, Avishek Chatterjee, Kehui Wang, Samia Dakhia (London, UK)

Scientific Posters

Treatment Strategies: RCTS: oral and injectable therapy in first-line and suppressed switch populations (continued)

P060	**Resistance analysis at week 48 of daily doravirine/islatravir (100 mg/0.25 mg) versus bictegravir/ emtricitabine/tenofovir alafenamide in a blinded phase 3 study in adults Initiating treatment for HIV-1** Tracy Diamond, Uchechukwu Nwoke, Tarak Patel, Yayun Xu, Stephanie Klopfer, Mary Vesnesky, Luisa Stamm, Michelle Fox, Mary Pisculli, Ernest Asante-Appiah (Rahway, NJ, USA)
P061	**Long-term outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence and patient-reported outcomes from people with HIV-1 in the CARLOS study 3 years post-switch** Sebastian Noe, Celia Jonsson-Oldenbüttel, Christoph Wyen, Jan Borch, Kevin Ummard-Berger, Christiane Cordes, Stefan Scholten, Niels Schübel, Alexa Pfauth, Bernd Westermayer, Jenny Scherzer (Munich, Germany)
P062	**Characterising viraemic events in the ARTISTRY-1 and ARTISTRY-2 trials** Peter Ruane, Eric Meissner, Edwin DeJesus, Dai Watanabe, Ying Guo, Kwad Mponponsuo, Jairo M Montezuma-Rusca, Peter Sklar, Chloe Orkin (London,UK)
P063	**Patient-reported outcomes with doravirine/islatravir (100/0.25 mg) once daily versus bictegravir/ emtricitabine/tenofovir alafenamide in virologically suppressed adults living with HIV-1: phase 3 results through week 96** Gary I Sinclair, Amy E Colson, Moti N Ramgopal, Craig A Dietz, Anthony LaMarca, Alexandra W Dretler, Chloe Orkin, Philip Bright, Andrew Carr, Takuma Shirasaka, Chenguang Zhang, Michelle C Fox, Mengchun Li, Girish Prajapati (Dallas, TX, USA)
P064	**Comparative efficacy and safety of doravirine/islatravir versus contemporary ART regimens in virologically suppressed people living with HIV-1 at 48 weeks: a systematic review and network meta-analysis** Alex Karagiannis, Girish Prajapati, Abdel Hmissi, Kate Young, Nick Halfpenny, Megha Garg, Sean Fleming (Zurich, Switzerland)
P065	**Abstract withdrawn**
P066	**Home-based versus hospital-based long-acting cabotegravir/rilpivirine: results from the randomized ALADDIN trial** Silvia Nozza, Maria Vittoria Bufali, Angelo Roberto Raccagni, Nicolò Capra, Riccardo Lolatto, Valentina Lovato, Flavia Badalucco, Elena Bruzzesi, Tommaso Clemente, Vincenzo Spagnuolo, Antonella Castagna, Oriana Ciani (Milan, Italy)
P067	**Case study of a patient on subcutaneous long-acting cabotegravir and rilpivirine** Arno Beer, Stefan Lung, Iris Kremser, Alexander Egle (Salzburg, Austria)
P068	**Two-year follow-up of people living with HIV receiving long-acting CAB/RPV: impact on wellbeing?** Anna Carraro, Vanessa Bertocchi, Raffaella Marocco, Lorenzo Ansaldo, Vito Speciale, Giulia Mancarella, Cosmo Del Borgo, Miriam Lichtner (Rome, Italy)
P069	**Abstract withdrawn**

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy

P070	**High virologic suppression and adherence with rare virologic failure in treatment experienced virologically suppressed individuals on cabotegravir+rilpivirine: results from the COMBINE-2 European cohort** Anton Pozniak, Gayathri Sridhar, Lambert Assoumou, Ana González-Cordón, Eugènia Negredo, Nathalie De Castro, Myriam Diemer, Leigh Ragone, Ajay Shah, Jean van Wyk, Vani Vannappagari (Durham, NC, USA)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P071	**Real world data of effectiveness of dolutegravir plus lamivudine in treatment-naive people living with HIV: the ANA-DOLU cohort study** Ferit Kuscu, Aslihan Candevir, Ongun Yeniceri, Mustafa Kemal Celen, Suheyla Komur, Tuba Damar Cakirca, Damla Erturk, Cigdem Mermutluoglu, Ayse Seza İnal, Mehmet Cabalak, Ilkay Karaoglan, Elif Sahin Horasan, Ayse Ozlem Mete, Tugce Simsek Bozok, Behice Kurtaran, Yesim Tasova (Adana, Türkiye)
P072	**Real-world virological effectiveness and hepatitis B safety of switching to long-acting injectable cabotegravir and rilpivirine (LANTERN): a multicentre observational cohort study in Asia** Chien-Yu Cheng, Shin-Yen Ku, Jui-Hsuan Yang, Shu-Yuan Lee, Cheng-Pin Chen, Shu-Hsing Cheng, Jui-Hsing Wang, Chia-Jui Yang, Tsung-Chia Chen, Tung-Che Hung, Andrew Po-Liang Chen, Linghua Li, Wang-Huei Sheng, on behalf of LANTERN Study Group (Taoyuan City, Taiwan)
P073	**Polypharmacy in people with HIV over 50 compared to a matched control population and drug interactions with ART: results of the French Polypills study** Clotilde Allavena, Rocco Collarino, Philippe Mariot, Haydar Benachir, Stephanie Dousa, Aurelien Carlicchi, Augustin-Martin Gaigne, Patrice Muret (Nantes, France)
P074	**Cabotegravir plus rilpivirine in real-world evidence: a systematic literature review of outcomes following virological failure, including resistance and subsequent treatment options** Inês Augusto, John Thornhill, Ian Jacob, Patricia de los Rios, Bryn Jones (Algés, Portugal)
P075	**Abstract withdrawn**
P076	**Patient-reported burden of daily antiretroviral therapy and the lived experience of switching to cabotegravir+rilpivirine long-acting: mixed-methods findings from the VOLITION trial** Cassidy A Gutner, Ian Jacob, Julie Priest, Rekha Trehan, Anoushka Dugal, Avishek Chatterjee, Kehui Wang, Miguel Pascual-Bernaldez, Patricia de los Rios, Monika Bui, Kai Hove, Cheryl McDonald, Mezgebe Berhe, Jean van Wyk, Bryn Jones (Durham, NC, USA)
P077	**Staff perspectives on the burden of daily oral antiretroviral therapy and clinical implementation of switching to cabotegravir+rilpivirine long-acting: mixed-methods findings from the VOLITION trial** Cassidy A Gutner, Ian Jacob, Julie Priest, Rekha Trehan, Anoushka Dugal, Avishek Chatterjee, Kehui Wang, Miguel Pascual-Bernaldez, Patricia de los Rios, Monika Bui, Kai Hove, Cheryl McDonald, Mezgebe Berhe, Jean van Wyk, Bryn Jones (Durham, NC, USA)
P078	**Consistently high cabotegravir+rilpivirine long-acting persistence and effectiveness across ages and race/ethnicity in the US OPERA cohort** Ricky Hsu, Michael Sension, Jennifer Fusco, Laurence Brunet, Quateka Cochran, Gayathri Sridhar, Vani Vannappagari, Kimberley Brown, Jean Van Wyk, Michael Wohlfeiler, Gregory Fusco (Raleigh, NC, USA)
P079	**Beyond viral suppression: adherence challenges and unmet needs in people with HIV in the UK (Positive Perspectives 3 study)** Garry Brough, Mercy Shibemba, Liz Foote, Abdul Halim, Thomas Bendall, Ta-Fen Hwang, Chinyere Okoli, Nneka Nwokolo, Rickesh Patel, Ama Appiah (London, UK)
P080	**Not all dual INSTI-based regimens are equal: real-world durability and virological outcomes of DTG/3TC versus CAB/RPV** Camilla Muccini, Nicholas Brian Bana, Giulia Burastero, Leonardo Francesco Rezzonico, Andrea Forni, Elisa Di Gennaro, Maria Cristina Moioli, Massimo Puoti (Milan, Italy)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P081	**Non-RPV NNRTI RAMs are associated with virological failure in people with HIV receiving cabotegravir/rilpivirine** Camilla Muccini, Nicholas Brian Bana, Andrea Carbone, Simona Di Giambenedetto, Carlo Torti, Paolo Bonfanti, Fiore Artelli, Diego Ripamonti, Paola Vitiello, Clara Abeli, Giorgio Tiecco, Eugenia Quiros-Roldan, Massimo Puoti, Roberto Rossotti (Milan, Italy)
P082	**Impact of virological suppression status on immune recovery after switch to long-acting CAB/RPV** Camilla Muccini, Nicholas Brian Bana, Giulia Burastero, Francesco Leonardo Rezzonico, Paola Vitiello, Clara Abeli, Gaia Cologgi, Giorgio Tiecco, Eugenia Quiros-Roldan, Laura Comi, Giuseppe Lapadula, Paolo Bonfanti, Massimo Puoti, Roberto Rossotti (Milan, Italy)
P083	**Comparison of virological success and immunological recovery of LAI CAB/RPV versus DOR/3TC/TDF in virologically suppressed people with HIV** Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, Valentina Iannone, Sasha Trevisan, Pierluigi Francesco Salvo, Andrea De Vito, Maddalena Matone, Massimiliano Fabbiani, Gabriella d'Ettorre, Stefano Rusconi, Filippo Lagi, Alberto Borghetti, Chiara Papalini, Giordano Madeddu, Spinello Antinori, Andrea Gori, Cristina Mussini, Simona Di Giambenedetto (L'Aquila, Italy)
P084	**Comparative effectiveness, durability and immunological outcomes of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naïve people with HIV** Arturo Ciccullo, Gianmaria Baldin, Maria Vittoria Cossu, Alberto Zuppiroli, Adriana Cervo, Francesca Lombardi, Andrea De Vito, Valentina Iannone, Marianna Menozzi, Gabriella d'Ettorre, Maria Aurora Carleo, Alberto Borghetti, Pierluigi Viale, Cristina Mussini, Spinello Antinori, Simona Di Giambenedetto (L'Aquila, Italy)
P085	**Early dolutegravir/lamivudine switch versus continued bictegravir-based therapy following virological suppression in a real-life cohort** Arturo Ciccullo, Gianmaria Baldin, Andrea Giacomelli, Adriana Cervo, Virginia Donini, Letizia Oreni, Marianna Menozzi, Vincenzo Esposito, Massimiliano Fabbiani, Annamaria Cattelan, Alberto Zuppiroli, Giordano Madeddu, Stefano Rusconi, Filippo Lagi, Spinello Antinori, Cristina Mussini, Simona Di Giambenedetto (L'Aquila, Italy)
P086	**Factors associated with non-treatment with antiretroviral therapy among people living with HIV COCOVIH2** Catherine Majerholc, François Prevoteau du Clary, Jean-Michel Livrozet, David Zucman, Camille Nevoret, Stéphane Bouee, Pierre Leroy (Suresnes, France)
P087	**DISCONT-LA: interim analysis of discontinuation on long-acting injectable in clinical practice conditions** Neus Gómez-Muñoz, Marco Fernández-Blest, Ana Moreno-Zamora, Santos del-Campo-Terrón, Vicente Estrada-Pérez, Noemi Cabello-Clotet, Maria José Galindo, Miguel Torralba, Daniel Collado, Marian Fernández-López, Naya Faro, Jesús Vera-Méndez, Robert Güerri, Antonio Agustí Adrover, Clara Munoz, Javier Leal-Martínez-Bujanda, Keith Dunn, Miguel García-Deltoro (Valencia, Spain)
P088	**Real-world outcomes of patients living with HIV and M184 mutations switched to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)** Dominic Haigh, Jacob Smiles, Nathan Jacobs, Anna Garner, Orla McQuillan, Ashley McEwan, Peter Tilston, Shazaad Ahmad (Manchester, UK)
P089	**Estimating the prevalence of non-suppressible viremia in adults living with HIV-1 using a novel diagnostic screenings assay** Jolanda Voermans, Jolieke van Osch, Robin Huisman, Laura van Schouwenburg, Bart Rijnders, Adam Anas, Hannelore Bax, Dorine de Vries, Karin Schurink, Jan Nouwen, Eric van Gorp, Mariana de Mendonca Melo, Lennert Slobbe, Els van Nood, Widia Soochit, Daphne Mulders, Carlos Grasa, Pieter Fraaij, Casper Rokx, David van de Vijver, Rob Gruters, Thibault Mesplede, Jeroen van Kampen (Rotterdam, Netherlands)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P090	**Characterising resistance-associated mutations and virological status among people living with HIV receiving regimens containing bictegravir, cabotegravir or dolutegravir** Sara N Levintow, Paul McDwyer, Ziwei Yin, Wenyi Wang, Michelle L D'Antoni, Travis Lim (Foster City, CA, USA)
P091	**Understanding perspectives and experiences of older people living with HIV: survey findings from the Ask Us Europe study** Chloé Pasin, Megan Devonald, Melanie Smuk, Rebecca Mbewe, Angelina Namiba, Marcel Dams, Matthew Hodson, Nicoletta Policek, Alain Volny Anne, Luís Mendão, Marta Boffito, Simon Collins, Tristan Barber, Giovanni Guaraldi, Alexandra Calmy, Stefan Scholten, Silvia Nozza, Ben Collins, Christophe Rouquette, Sarah Brunel, Thierry Tran, Chloe Orkin, on behalf of Ask Us Steering Group (London, UK)
P092	**96-week effectiveness and tolerability of long-acting injectable cabotegravir plus rilpivirine in young adults with perinatally acquired HIV: a substudy of the RELATIVITY cohort** Alejandro de Gea Grela, Noemi Cabello, María José Galindo, Jesús Troya, Rosa María Martínez Álvarez, María Remedios Alemán, María de Lagarde, Miguel Torralba, Luis Buzón, María José Crusells, Francisco Fanjul, Adrián Rodríguez, Raúl Parra Fariñas, Mireia Cairó, María del Carmen Navarro, Ignacio De los Santos, Carmen Hidalgo, Luis Enrique Morano, Enrique Bernal, David Vinuesa, María Josefa de la Asunción, Lucia Fito, Hadrián Pernas, María Jesús Vivancos, José Ignacio Bernardino, on behalf of RELATIVITY Cohort Study Group (Madrid, Spain)
P093	**Detected but not predictive? Baseline NGS resistance and virological suppression with B/F/TAF in treatment-naïve people with HIV** Giovanni Massobrio, Marianna Giurco, Vincenzo Paolozzi, Eleonora Pratolongo, Valentina Ricucci, Federica Stefanelli, Nadia Randazzo, Matteo Bassetti, Lucia Taramasso, Antonio Di Biagio (Genoa, Italy)
P094	**Patient-reported outcomes in treatment-naïve people with HIV initiating B/F/TAF: a pooled analysis of the BICSTaR cohort** Benoit Trottier, Deniz Gökengin, Diana Canetti, Tomoyuki Endo, Shu-Hsing Cheng, Eynat Kedem, Antonio Antela López, Jan den Hollander, Daniel Beer, Arthur Jackson, Arnaud Desclaux, David Thorpe, Andrea Marongiu, Rebecca Harrison, Mo Hu, Yeon-Sook Kim (Uxbridge, UK)
P095	**BICSTaR: 24-month effectiveness and tolerability of B/F/TAF by HIV diagnosis era** Itzchak Levy, Katsuji Teruya, Marta Boffito, Chia-Jui Yang, Giulia Marchetti, Miguel Garcia Deltoro, Malcolm Hedgcock, Roger Vogelmann, Laurent Hocqueloux, Arthur Jackson, Shin-Woo Kim, Chiaw Yee Choy, Ahmet Çağkan Ínkaya, David Thorpe, Andrea Marongiu, Tali Cassidy, Berend van Welzen (London, UK)
P096	**Effectiveness of using a multidisciplinary care model for engaging unstable individuals in HIV treatment with bictegravir/emtricitabine/tenofovir alafenamide** Christina Wiesmann, Shana Yi, David Truong, Brian Conway (Burnaby, Canada)
P097	**Patient-reported HIV symptoms distress decreases after switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected marginalized individuals living in Vancouver, Canada** Christina Wiesmann, David Truong, Brian Conway (Burnaby, Canada)
P098	**Investigation of the effectiveness of a once-a-day bictegravir/emtricitabine/tenofovir alafenamide treatment regimen in combination with a multidisciplinary model of care for improving HIV viral suppression** Christina Wiesmann, David Truong, Brian Conway (Vancouver, Canada)
P099	**Novel bioinformatic pipeline identifies INSTI resistance mutation G140R as a minority variant in HIV-1 sub-subtype A6 and distinguishes between APOBEC hypermutation and true DRM** Anna Weibull Wärnberg, Bryant Oh Zhi Yang, Annie Hsieh, Piotr Nowak, Anders Sönnerborg, Emmi Andersson, Maarten van de Klundert (Stockholm, Sweden)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P100	**Long-acting cabotegravir plus rilpivirine in a large single-centre cohort: high virological efficacy including in people without baseline resistance testing** Miguel Araújo Abreu, Rita de Almeida Teixeira, Carolina Costa, João Matos, Joana Vaz Cardoso, Josefina Méndez (Porto, Portugal)
P101	**Outpatient or hospital-based care for long-acting injectable antiretroviral therapy: different preferences, different reasons, but equal satisfaction – the real-life PANTER study** Tristan Alain, Fabienne Marcellin, Saleh Ali, Carole Abeguille, Claudine Duvivier, Valérie Pourcher, Pascale Perfezou, Wiem Loghmari Bouchneb, Anais Lesourd, Gwenael Le Moal, Martin Duracinsky (Paris, France)
P102	**Comparison of dolutegravir/lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients with high viral load: a multicentre retrospective study** Joon Young Song, Jun Yong Choi, Dae Won Park, Shin-Woo Kim, Ji Young Rhee, Dong Hoon Shin, Sun Hee Lee, Tae Hyong Kim, Eun Jin Kim, Jihyeon Baek, Kyung-Hwa Park, Yeon-Sook Kim, on behalf of Rose of Sharon Study Group (Daejeon, Republic of Korea)
P103	**Tolerability following the first injection satisfaction of long-acting cabotegravir plus rilpivirine in virologically suppressed people with HIV aged ≥ 60 years: the LOVER60 trial** Salvador Valero Cifuentes, Helena Albendin Iglesias, Francisco Vera Méndez, Joaquín Bravo Urbieta, Sergio Padilla, Sergio Reus, Concepción Gil Anguita, Raque Garijo, Antonia Alcaraz Garcia, Antonia Castillo Navarro, Onofre Martínez Madrid, Isabel Carpena Martínez, Javier Garcia Abellan, Livia Giner Oncina, Isabel Ribas Mengual, Angeles Muñoz Perez, Maria Angeles Fernandez Lopez, Lorena Martinez, Maria Dolores Hernandez Lorente, Paula Mascarell, Jimena Teran, Cristina Tomas Jimenez, Carlos Galera Peñaranda, Rosa Blazquez Garrido, Esperanza Merino, Enrique Bernal Morell (Murcia, Spain)
P104	**Hepatic steatosis and fibrosis in people with HIV aged ≥ 60 years eligible for long-acting cabotegravir plus rilpivirine: baseline findings from the LOVER60 trial** Salvador Valero Cifuentes, Helena Albendin Iglesias, Francisco Vera, Joaquin Bravo Urbieta, Sergio Padilla, Sergio Reus, Concepción Gil Anguita, Jose E Martin-Herrero, Eva Garcia Villalba, Antonia Castillo Navarro, Onofre Martinez, Sergio Aleman, Javier Garcia Abellan, Livia Giner Oncina, Isabel Ribes Mengual, Jose Miguel Gomez Verdu, Maria Angeles Fernandez Lopez, Lorena Martinez, Monica Martinez Martinez, Paula Mascarell, Jimena Teran, Rodrigo Martinez Rodriguez, Carlos Galera Peñaranda, Antonio Sanchez Guirao, Enrique Bernal Morell (Murcia, Spain)
P105	**Comorbidity and frailty assessed by the FRAIL scale in people with HIV aged ≥ 60 years switching to long-acting cabotegravir plus rilpivirine: baseline results from the LOVER60 trial** Salvador Valero Cifuentes, Helena Albendin Iglesias, Francisco Vera, Joaquín Bravo Urbieta, Sergio Padilla, Sergio Reus, Concepción Gil Anguita, Maria Jesus Vazquez, Rebeca Mondaray-Marin, Antonia Castillo Navarro, Onofre Martinez Madrid, Isabel Carpena, Javier Garcia Abellan, Livia Giner Oncina, Isabel Ribes Mengual, Antonia Alcaraz Garcia, Maria Angeles Fernandez Lopez, Lorena Martinez, Maria Dolores Hernandez Lorente, Paula Mascarell, Jimena Teran, Angeles Muñoz Perez, Carlos Galera Peñarnada, Rosa Blazquez Garrido, Enrique Bernal Morell (Murcia, Spain)
P106	**Resistance burden and treatment optimisation potential in heavily treatment-experienced people living with HIV: a real-world genotypic analysis** Alejandro De Gea -Grela, Jose I Bernardino, Jara Llenas-Garcia, Luz Martin-Carbonero, Maria Luisa Montes, María del Mar Arcos Rueda, Rosa De Miguel-Buckley, Carmen Busca, Rafael Mican, Juan Gonzalez-Garcia, Jose R Arribas, Rocio Montejano (Madrid, Spain)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P107	**Cardiometabolic and body-composition outcomes in people with HIV switching to long-acting cabotegravir plus rilpivirine versus oral two-drug regimens: a matched cohort study** Filippo Calandra Buonaura, Jovana Milic, Uberto Calvi, Filippo Buffagni, Eugenio Carriero, Cristina Mussini, Giovanni Guaraldi (Modena, Italy)
P108	**Safety and effectiveness results of post-marketing surveillance studies of B/F/TAF in China, Japan and Republic of Korea** Jami Peters, Jennifer Davidson, Margarida Serejo, Keith Aizen, Nao Taguchi, Jeong-a Lee, Yixiao Lin, Mellissa Williamson (Foster City, CA, USA)
P109	**Real world outcomes following switch from boosted protease inhibitor based antiretroviral therapy regimens to dolutegravir/lamivudine** Thomas Swaine, Alan Hunter, Shenal Gohil, Fiona Burns, Tristan Barber (London, UK)
P110	**The prevalence of risk factors for long-acting injectable antiretroviral therapy (CAB+RPV) failure in a Polish multicentre cohort** Andrzej Załęski, Michał Dowiatt, Agnieszka Lembas, Marta Dobrzyńska, Justyna Orzechowska, Aldona Kot, Joanna Stempkowska-Rejek, Joanna Osińska, Marcin Dręczewski, Tomasz Dyda, Alicja Wiercińska-Drapało (Warsaw, Poland)
P111	**Why different individuals develop resistance to different drugs on dolutegravir-based HIV therapy** Germander Soothill, Lanxin Zhang, Sara Iannuzzi, Tom Loosli, Matthias Egger, Roger Kouyos, Max von Kleist, Andrew Leigh Brown, Katherine E Atkins (Edinburgh, UK)
P112	**Community pharmacy readiness for delivery of long-acting injectable HIV pre-exposure prophylaxis in Uganda** Jonathan Derrick Lukubuya, Eva Agnes Laker Odongpiny, Elizabeth B Katana, Joseph Owori, Ivan Segawa, Freddy Eric Kitutu, Kalidi Rajab, Timothy R Muwonge, Katrina F Ortblad, Andrew Mujugira (Kampala, Uganda)
P113	**Preferred HIV PrEP formulation and delivery model for adolescent girls and young women in Fortportal City: a mixed methods study in Uganda** Jonathan Derrick Lukubuya, Eva Agnes Laker Odongpiny, Elizabeth B Katana, Joseph Owori, Ivan Segawa, Richard Muhindo, Stephen Okoboi, Katrina F Ortblad, Andrew Mujugira, Timothy R Muwonge (Kampala, Uganda)
P114	**Immunovirological outcomes in a cohort of migrants living with HIV: the impact of diagnosis setting and social vulnerability** Lara Neto, Constança Azeredo, Cristina Soeiro, Clara Batista, Eduarda Pena, Isabel Neves, Maria João Gonçalves, Mário Guimarães, Sofia Jordão, Sónia Duarte Rocha, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal)
P115	**Four-year experience with long-acting cabotegravir–rilpivirine in a multicentre cohort in Italy: update from the LONGITUDE study** Francesco Vladimiro Segala, Lolita Sasset, Marina Malena, Alberto Zuppiroli, Silvia Cretella, Daniela Piacentini, Emanuela Lattuada, Stefano Nicolé, Giuliana Battagin, Fabio Rigo, Giada Fasani, Anna Rigo, Cinzia Puzzolante, Lorenzo Badia, Maria Mazzitelli, Mariacristina Rossi, Massimiliano Lanzafame, Leonardo Calza, Cristina Mussini, Annamaria Cattelan, on behalf of LONGITUDE Study Group (Padua, Italy)
P116	**Long-acting cabotegravir and rilpivirine in routine clinical practice: virological outcomes and patient-reported reasons for switching from oral antiretroviral therapy** Tiago Neves, Ana Martins, Gonçalo Cruz, Helena Alves, Sandra Tejo, Cristina Valente (Coimbra, Portugal)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P117	**Geographic and socioeconomic determinants of long-acting cabotegravir plus rilpivirine access and outcomes: a real-world cohort study from southern Spain** Claudia Ferreira-Tata, Laura Ruiz-Torres, Diana Corona-Mata, Angela Camacho, Marina Gallo, Andres Baumela, Isabel Carmona, Antonio Doblas, Antonio Rivero, Ignacio Perez-Valero (Cordoba, Spain)
P118	**Real-world outcomes with long-acting cabotegravir plus rilpivirine in people with HIV-1 aged ≥ 50 years: a systematic literature review** Andrea Calcagno, Kristine Erlandson, Inês Augusto, Ian Jacob, Patricia de Los Rios, Santiago Cenoz Gomis, Ta-Fen Hwang, Bryn Jones (Novara, Italy)
P119	**CABO-CHANCE: long-acting cabotegravir plus rilpivirine in ART-experienced people with HIV (24-month real-world outcomes)** Carmen Hidalgo-Tenorio, Maria Aguilera-Garcia, Ignacio De los Santos, Andres Ruiz-Sancho, Antonio Rivero, Ana Lopez Lirola, Mohamed Omar, Alberto Romero, Enrique Bernal, Onofre Martinez, Teresa Lopez, Patricia Sorni, Paula Garcia Ocaña, Santiago Moreno, Isabel SanJoaquin, Jose Ramón Blanco, Coral Garcia Vallecillos (Granada, Spain)
P120	**Real-world virologic effectiveness outcomes with long-acting cabotegravir plus rilpivirine in women: a systematic literature review** María Galindo Puerto, William Short, Inês Augusto, Ian Jacob, Emilio Letang, Patricia de los Rios, Chinyere Okoli, Bryn Jones (Valencia, Spain)
P121	**Real world implementation of long-acting cabotegravir and rilpivirine in UK NHS HIV clinics** Claire Norcross, Clea Tanner, Kate Alford, Kyle Ring, Ankur Gupta-Wright, Bazga Ali, Dan Clutterbuck, Julie Fox, Emily Clarke, Alison Uriel, Jill Dixon, Paola Cicconi, Jaime Vera, Caroline Sabin, Fiona Cresswell (Brighton, UK)
P122	**HBV surveillance after switch to long-acting injectable antiretroviral therapy in people living with HIV. Are we monitoring adequately?** Luísa Lopes, Gonçalo Silva, Inês Gonçalves, Filipe Medeiros, Hugo Graça, Joana Marinho, Cristina Valente (Coimbra, Portugal)
P123	**Immunological and neuroinflammatory profile of long-acting cabotegravir/rilpivirine in people with HIV: a 24-month study** Maria Antonella Zingaropoli, Mariasilvia Guardiani, Anna Carraro, Eeva Tortellini, Federica Dominelli, Michele Antonacci, Cosmo Del Borgo, Raffaella Marocco, Giulia Mancarella, Lorenzo Ansaldo, Ombretta Turriziani, Maria Rosa Ciardi, Claudio Maria Mastroianni, Serena Vita, Miriam Lichtner (Rome, Italy)
P124	**Virological failure classification under the CONSENSUS-LAI definition: real-world data from the multicentre LAHIV cohort** Filippo Lagi, Barbara Rossetti, Sasha Trevisan, Massimiliano Fabbiani, Matteo Piccica, Alessio Pampaloni, Sara Modica, Beatrice Menichini, Silvia Costarelli, Claudia Bianco, Giovanni Sarteschi, Michele De Gennaro, Martina Turco, Virginia Donini, Martina Maruotto, Paola Corsi, Marco Pozzi, Mario Tumbarello, Daniela Messeri, Cecilia Costa, Beatrice Anna Adriani, Cesira Nencioni, Danilo Tacconi, Spartaco Sani, Antonella Vincenti, Luigi Pisano, Filippo Bartalesi, Alessandro Bartoloni (Florence, Italy)
P125	**Real-world durability and discontinuation patterns of long-acting cabotegravir/rilpivirine in Tuscany: three-year data from the LAHIV multicentre cohort** Filippo Lagi, Sasha Trevisa, Massimiliano Fabbiani, Barbara Rossetti, Matteo Piccica, Alessio Pampaloni, Sara Modica, Beatrice Menichini, Silvia Costarelli, Claudia Bianco, Giovanni Sarteschi, Michele De Gennaro, Martina Turco, Virginia Donini, Maruotto Martina, Paola Corsi, Marco Pozzi, Mario Tumbarello, Daniela Messeri, Cecilia Costa, Beatrice Anna Adriani, Cesira Nencioni, Danilo Tacconi, Spartaco Sani, Vincenti Antonella, Luigi Pisano, Filippo Bartalesi, Alessandro Bartoloni (Florence, Italy)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P126	**Two-year metabolic and immunological profile of long-acting cabotegravir/rilpivirine in real-world practice: data from the LAHIV cohort** Filippo Lagi, Martina Maruotto, Barbara Rossetti, Matteo Piccica, Giovanni Sarteschi, Alessio Pampaloni, Beatrice Menichini, Margherita Sambo, Silvia Costarelli, Claudia Bianco, Michele De Gennaro, Sara Modica, Paola Corsi, Marco Pozzi, Martina Turco, Mario Tumbarello, Sasha Trevisan, Cecilia Costa, Beatrice Anna Adriani, Cesira Nencioni, Daniela Messeri, Danilo Tacconi, Spartaco Sani, Antonella Vincenti, Luigi Pisano, Filippo Bartalesi, Alessandro Bartoloni (Florence, Italy)
P127	**Examining the healthcare burden of antiretroviral therapy resistance among people with HIV in the US** Hansel Tookes, Garrett Gremel, Uche Mordi, Mary Christoph, Michelle D'Antoni, Sara Levintow, Eva Culakova, Woodie Zachry, Joshua Cohen (Foster City, CA, USA)
P128	**CD27 and PD-1 expression patterns and ratio-based assessment of immune exhaustion in people living with HIV** Veysel Akca, Burak Ekrem Çitil, Turhan Togan (Sandıklı, Türkiye)
P129	**Long-acting injectable cabotegravir/rilpivirine in migrant people living with HIV: uptake, barriers and social vulnerability as a driver of adoption** Lara Neto, Cristina Soeiro, Clara Batista, Eduarda Pena, Maria João Gonçalves, Sofia Jordão, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal)
P130	**Five-year persistence and reasons for discontinuation of dolutegravir/lamivudine in a multicentre real-world cohort of people living with HIV** Emma Vallribera Olmos, Marta Escura Esteban, Maria del Carmen Navarro Sáez, Sonia Calzado Isbert, Marc Pedrosa Aragon, Lizza Maria Macorigh Mantilla, Elisabet Deig Comerma, Julia Gutierrez Sanjuan, Rodrigo Alonso Navarro, Oscar Del Rio Perez, Silvia Valero Rovira, Marta Navarro Vilasaró (Sabadell, Spain)
P131	**Residual viremia in adults receiving contemporary antiretroviral therapy: a real-world Brazilian cohort** Pietra Stanicki, Karen Ingrid Tasca, Alexandre Naime Barbosa
P132	**Towards elimination of HIV, syphilis and HBV mother-to-child transmission in the Gambia and Burkina Faso: the triple elimination model of mother-to-child transmission (TRI-MOM) programme** Abdoulie E Jallow (Banjul, Gambia)
P133	**Bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve people with HIV: 48-week real-world outcomes including very high baseline viraemia** Aysin Kilinc Toker, Hande Saglam Eslik, Merve Sultan Akpinar, Zehra Gul Koca, Aysenur Kefkir, Ahmed Hatip (Kayseri, Türkiye)
P134	**Effectiveness of DTG/3TC as simplification strategy in a multicentric virologically suppressed cohort of people with HIV with a current CD4 count below 350 cells/mmc** Gianmaria Baldin, Francesca Lombardi, Adriana Cervo, Alberto Borghetti, Massimiliano Fabbiani, Arturo Ciccullo, Filippo Lagi, Letizia Oreni, Francesco Bassani, Stefano Rusconi, Andrea Gori, Cristina Mussini, Simona Di Giambenedetto, Andrea Giacomelli (Roma, Italy)
P135	**Long-term viral reservoir, T-cell homeostasis, inflammation and mitochondrial damage in people with HIV switching to long-acting injectable cabotegravir/rilpivirine** Matteo Augello, Valeria Bono, Chiara Orlandi, Roberta Rovito, Valentina Sala, Camilla Tincati, Anna Casabianca, Giulia Marchetti (Milan, Italy)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)

P136	**Real-world effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV in Belgium: a 144-week analysis** Rakan Nasreddine, Maartje van Frankenhuijsen, Jean Cyr Yombi, Marie-Angélique De Scheerder, Peter Messiaen, Gilles Darcis, Nathalie Ausselet, Jens Van Praet, Sabine D Allard, Rémy Demeester, Marc Delforge, Stéphane De Wit, on behalf of Belgian Research on AIDS & HIV Consortium (Brussels, Belgium)
P137	**Abstract withdrawn**
P138	**Beyond viral suppression: sustained reductions in T-cell activation and senescence after switching to long-acting cabotegravir/rilpivirine over 36 months in people living with HIV** Martina Proietti, Mariasilvia Guardiani, Federina Dominelli, Anna Carraro, Eeva Tortellini, Lorenzo Ansaldo, Maria Antonella Zingaropoli, Michele Antonacci, Vito Speciale, Fabio Mengoni, Giulia Mancarella, Andrea Gasperin, Marco De masi, Serena Vita, Claudio Maria Mastroianni, Raffaella Marocco, Cosmo Del Borgo, Miriam Lichtner (Rome, Italy)
P139	**Abstract withdrawn**
P140	**Real-world effectiveness and patient-reported outcomes of long-acting cabotegravir–rilpivirine in people with HIV in South Korea: a prospective observational study** Hyeongseok Jeong, Shinhye Cheon, Younghee Jung, Yeon-Sook Kim (Daejeon, Republic of Korea)
P141	**Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in older people living with HIV: real-world evidence from Saudi Arabia** Roaa Alosaimi, Batool Ali, Tala Galai, Ibrahim Alshehri, Alaa Malki, Osama Alghamdi (Jeddah, Saudi Arabia)
P142	**Supporting individualised treatment strategies with NGS: eligibility for islatravir/doravirine in ART-naïve individuals** Marianna Giurco, Giovanni Massobrio, Vincenzo Paolozzi, Valentina Ricucci, Federica Stefanelli, Nadia Randazzo, Lucia Taramasso, Matteo Bassetti, Antonio Di Biagio (Genoa, Italy)
P143	**Albuvirtide enhances immune recovery in treatment-naive patients with advanced HIV infection receiving bictegravir/emtricitabine/tenofovir alafenamide: a retrospective propensity score-matched cohort study** Yingchun Zhu, Huanxia Liu, Yin Wang, Zongzheng Wang, Lin Cai (Chengdu, China)
P144	**Demographics, clinical characteristics and treatment patterns of people with HIV who are virologically suppressed receiving complex regimens in Japan: a real-world database study using electronic medical records** Soodi Navadeh, Nao Taguchi, Jesse Najarro Cermeno, Reiko Yamaura, Siming Chen, Mellissa Williamson, `Peter Sklar, Dai Watanabe (Foster City, CA, USA)
P145	**Patient-reported outcomes following switch to long-acting cabotegravir+rilpivirine in Nordic clinical care: results from the VALHALLA study** Liisa Lehtoranta, Anne-Mette Lebech, Jussi Sutinen, Inka Aho, Raquel Martin-Iguacel, Ellen Moseholm, Alex Lund Laursen, Anders Krifors, Piotr Nowak, Steffen Leth, Jamirah Nazziwa, Hassan Aladdin, Felipe Rogatto, Jenny Scherzer, Melanie Schroeder (Helsinki, Finland)
P146	**Real-world experience with long-acting cabotegravir/rilpivirine in people living with HIV and historical rilpivirine resistance-associated mutations** Carolina Costa, Rita de Almeida Teixeira, João Matos, Joana Vaz Cardoso, Miguel Araújo Abreu, Josefina Méndez (Porto, Portugal)

Scientific Posters

Treatment Strategies: Real-world and implementation science studies, oral and injectable therapy (continued)	
P147	**Long-acting cabotegravir/rilpivirine experience in a Portuguese hospital: effectiveness, tolerability and hepatitis B risk stratification** Margarida Almeida, Constança Antunes, Ana Isabel Duarte, Bruno Rebelo, Margarida Falcão, João Alves, Ana Cláudia Miranda (Lisbon, Portugal)
P148	**Long-acting injectable antiretroviral therapy acceptance and associated factors in South Korea: a single-centre one year experience** BumSik Chin, Gayeon Kim, Min-Kyung Kim, Yeonjae Kim (Seoul, Republic of Korea)
P149	**Clinical context and early outcomes of switching the ART regimen of migrant people with HIV to B/F/TAF: the ASAP-Switch study** David Lessard, Serge Vicente, Kim Engler, Joel Ishak, Moustafa Laymouna, Kathy Nodzynski, Valérie Martel-Laferrière, Jean-Pierre Routy, Sean Yaphe, Alexandra de Pokomandy, Bertrand Lebouché (Montreal, Canada)
P150	**Patient perceptions of real-world use of CAB+RPV LA therapy in Canada** Arthi Rudak, Jean-Francois Fortin, Jonathan Smith, Mistre Alemayehu, Maria Esther Perez Trejo, Dorothée Chopamba, Mona Loufty (Mississauga, Canada)
Treatment Strategies: Treatment experienced adults (second-line and multi-drug resistance studies)	
P151	**Discordance between historical viral and proviral resistance testing and its impact on B/F/TAF genotypic susceptibility scores in the BRACE study** Eva Wolf, Martin Daeumer, Markus Bickel, Sebastian Noe, Christoph Wyen, Christoph Stephan, Neel Petersen, Stephan Grunwald, Patrick Braun, Sandra Schreiber, Stefan Esser, Katja Roemer, Claudia Pehlivan, Olaf Degen, Alexander Thielen, Annamaria Balogh, Christian Hoffmann (Munich, Germany)
P152	**Legacy ART in 2024-2025: clinical necessity, individual vulnerability or prescribing inertia?** Alessandra Vergori, Alessandro Tavelli, Andrea Giacomelli, Stefano Rusconi, Silvia Nozza, Valentina Mazzotta, Giuseppe Lapadula, Stefano Bonora, Giordano Madeddu, Roberta Gagliardini, Andrea Antinori, Antonella D'Arminio Monforte, Sergio Lo Caputo, on behalf of ICONA Cohort Study Group (Foggia, Italy)
P153	**Eligibility for islatravir-containing regimens in people living with HIV-1 experiencing virological failure under combined antiretroviral therapy: data from the ARCA cohort** Marianna Menozzi, Valeria Micheli, Omar El Khalili, Antonia Bezenchek, Valentina Ricucci, Bianca Bruzzone, William Gennari, Ilaria Vicenti, Cristina Mussini, Franco Maggiolo, Andrea De Vito, Francesca Ceccherini-Silberstein, Barbara Rossetti, Maria Mercedes Santoro, Daniele Armenia (Modena, Italy)
P154	**Metabolic and liver outcomes through week 48 following switch to dolutegravir/lamivudine in older, ART-experienced adults: the phase 3b EYEWITNESS study** Moti Ramgopal, Josefina Mendez, Laurence Slama, Manuel Crespo Casal, Guilia Marchetti, Bliss Leverette, Kehui Wang, Alex Pitchford, Richard Grove, Riya Moodley, Emilio Letang, Ana Milinkovic, Jean van Wyk, Piotr Budnik, Parul Patel (London, UK)
P155	**Outcomes of doravirine (DOR) based regimens in virologically suppressed ART-experienced patients: data from the ICONA cohort** Alessandro Tavelli, Antonella d'Arminio Monforte, Ilaria Mastrorosa, Roberta Gagliardini, Lucia Taramasso, Nicolas Brian Bana, Nicola Squillace, Teresa Bini, Daniela Segala, Eugenia Quiros-Roldan, Sergio Lo Caputo, Annalisa Saracino, Andrea Antinori, on behalf of ICONA Cohort Study Group (Milan, Italy)
P156	**Transmitted and acquired drug resistance in migrants living with HIV initiating care: prevalence, patterns and clinical implications** Lara Neto, Cristina Soeiro, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal)

Scientific Posters

Treatment Strategies: Treatment experienced adults (second-line and multi-drug resistance studies) (continued)

P157	**Evaluation of fostemsavir switch therapy in treatment experienced patients with HIV: real-world insights** Alison Duncan, Kate Mackie, James McMahon, Rekha Pai Mangalore (Melbourne, Australia)
P158	**Rapid improvement by day 8 in CD4/CD8 ratio with fostemsavir treatment in individuals with multidrug-resistant HIV-1** Judith Aberg, Michelle Moorhouse, Gustavo Verdier, Hemlata Pant, Neetu Badhoniya, Cynthia Donovan, Scott McCallister, Piotr Budnik, Manyu Prakash (London, UK)
P159	**Identifying and characterising people with HIV who are virologically suppressed and receiving complex regimens in Spain: the CoRIS cohort** Inmaculada Jarrín, Melchor Riera, Jose Ignacio Bernardino, Marta Rava, Adrian Curran, Sergio Reus Bañuls, Helena Albendín, Jesse Najarro Cermeño, Javier Leal Martinez-Bujanda, Neia Prata Menezes, Andrea Marongiu, Santiago Moreno Guillen, on behalf of the CoRIS cohort (Madrid, Spain)
P160	**Abstract withdrawn**
P161	**Characterization of non-canonical mutations in people with HIV experiencing persistent low-level viremia** Ilaria Vicenti, Ilenia Varasi, Lia Fiaschi, Luca Baldassari, Francesco Saladini, Laura Comi, Sara Soloperto, Maurizio Zazzi, Antonio D'Avolio, Diego Ripamonti (Bergamo, Italy)
P162	**Real-world effectiveness of long-acting cabotegravir plus rilpivirine in people living with HIV with a long treatment history and extensive prior antiretroviral exposure** Rodrigo de Almeida Mota, Cátia Caldas, Carmela Piñeiro, Rosário Serrão, Nélia Neves, Lurdes Santos (Porto, Portugal)
P163	**B-ALONE: bictegravir/emtricitabine/tenofovir alafenamide as a single-tablet regimen simplification in virologically suppressed people living with 4-class drug-resistant HIV: data from the PRESTIGIO Registry** Tommaso Clemente, Giovanni Festa, Riccardo Lolatto, Annamaria Cattelan, Antonio Di Biagio, Stefano Nardi, Nicolò Capra, Layla Pagnucco, Giancarlo Orofino, Cecilia Costa, Maria Mercedes Santoro, Antonella Castagna, on behalf of PRESTIGIO Study Group (Milan, Italy)
P164	**Proviral DNA genotyping reveals clinically relevant HIV drug resistance across the spectrum of low-level viremia: a nationwide cohort study** Pablo Ferrer, Alejandro Afani, Verónica Ramos (Santiago, Chile)
P165	**Efficacy and safety of switching to BIC/FTC/TAF plus DRV/cob versus DRV/r, RAL, TDF for maintaining virologic suppression in heavily-experienced patients with HIV-1** Marco Antonio Lopez Hernandez, Ericka Denise Bustos Angel, Juan Pablo Álvarez Mendoza (Mexico City, Mexico)
P166	**Identification of viraemic heavily treatment-experienced people with HIV who may benefit from optimized therapy using a clinical decision support system** Steven Barnett, Rachel Palmieri Weber, Jennifer Fusco, Michael Osterman, Courtney Sherman, Cindy Markarian, Mona-Gekanju Toeque, Ricky Hsu, Michael Sension, Adanna Oragwu, Seojin Park, Keith Dunn, Gregory Fusco (Tampa, FL, USA)
P167	**Predicted reduction in drug-drug interactions with bictegravir/lenacapavir compared to current complex regimens among people with HIV who were virologically suppressed: an OPERA cohort analysis** Anthony Mills, Michael Osterman, Rachel Weber, Gerald Pierone, Jr, Karam Mounzer, Michael Sension, Jennifer Fusco, Neia Prata Menezes, Rebecca Harrison, Priyanka Arora, Rachel Rogers, Bhumi Gandhi-Patel, Keith Dunn, Gregory Fusco (Raleigh, NC, USA)

Scientific Posters

Treatment Strategies: Treatment experienced adults (second-line and multi-drug resistance studies) (continued)

P168	**Clinical outcomes in people with HIV switching from oral dolutegravir-based two-drug regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): an analysis from the Italian ICONA Foundation cohort** Andrea De Vito, Alessandro Tavelli, Andrea Giacomelli, Andrea Costantini, Giancarlo Orofino, Riccardo Serraino, Raffaella Marocco, Roberto Rossotti, Silvia Nozza, Laura Albini, Gabriele Forcina, Alessandra Vergori, Antonio Di Biagio, Antonella d'Arminio Monforte, Giordano Madeddu, on behalf of ICONA Foundation Study Group (Sassari, Italy)
P169	**Abstract withdrawn**
P170	**Long-term effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from NNRTI-based antiretroviral therapy (ART) in virologically suppressed people with HIV: a retrospective analysis (DRIVE-SWITCH study)** Roberta Gagliardini, Marisa Fusto, Sandrine Ottou, Federica Forbici, Lavinia Fabeni, Giulia Del Duca, Martina Maresca, Alessandra Oliva, Fabrizio Maggi, Ilaria Mastrorosa, Maria Maddalena Plazzi, Federico De Zottis, Rita Bellagamba, Jessica Paulicelli, Carmela Pinnetti, Valentina Mazzotta, Roberto Caldera, Gabriele Forcina, Andrea Antinori (Rome, Italy)
P171	**Clustering of HIV-1 isolates based on index mutations detected in protease and integrase region: results from PRESTIGIO Registry** Sabrina Bagaglio, Nicolò Capra, Riccardo Lolatto, Tommaso Clemente, Stefano Bonora, Maurizio Celesia, Giulia Marchetti, Adriana Cervo, Antonio Di Biagio, Giovanni Cenderello, Maria Mercedes Santoro, Maurizio Zazzi, Antonella Castagna, Vincenzo Spagnuolo, on behalf of PRESTIGIO Study Group (Milan, Italy)
P172	**Real-world prescribing in M184V with additional NRTI resistance: heterogeneity in practice and the need for wider cohort data** Ciara Hickey, Paul Hine (Liverpool, UK)

Treatment Strategies: Models of care for ageing/frail populations including virological failure and switching

P173	**Healthcare trajectories among ageing people living with HIV: a multistate analysis from the Swiss HIV Cohort study** Annalisa Marinosci, Marcel Stoeckle, Matthias Cavassini, Roger Kouyos, Marius Zeeb, Bernard Surial, Andri Rauch, Patrick Schmid, Luigia Elzi, Aurore Thierry, Claire Coutureau, Alexandra Calmy, Maxime Hentzien (Geneva, Switzerland)
P174	**24-month effectiveness and persistence after switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV with comorbidities and polypharmacy** Maria Vittoria Cossu, Andrea Giacomelli, Davide Moschese, Letizia Oreni, Maddalena Matone, Giacomo Pozza, Giorgia Carrozzo, Annalisa Bergna, Andrea Poloni, Valeria Colombo, Anna Lisa Ridolfo, Agostino Riva, Laura Albini, Gabriele Forcina, Cristina Gervasoni, Andrea Gori (Milan, Italy)
P175	**Real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV experiencing socioeconomic precarity in France** Roland Landman, Lambert Assoumou, Aïda Benalycherif, Colin Deschanvres, Marc Digumber, Antoine Asquier Khati, Sylvie Legac, Thomas Jovelin, Aliou Balde, Jade Ghosn, Clotilde Allavena (Paris, France)
P176	**Long-term renal safety of INSTI single-tablet regimens in older people living with HIV** Lolita Sasset, Francesco Vladimiro Segala, Beatrice Bragato, Anna Ferrari, Eleonora Vania, Silvia Cavinato, Lucrezia Calandrino, Davide Leoni, Annamaria Cattelan (Padua, Italy)

Scientific Posters

Treatment Strategies: Models of care for ageing/frail populations including virological failure and switching (continued)	
P177	**Abstract withdrawn**
P178	**Effectiveness of dolutegravir/lamivudine according to the number of previous antiretroviral treatment lines in people with HIV older than 50 years** Emma Vallribera Olmos, Marta Escura Esteban, Sonia Calzado Isbert, Maria del Carmen Navarro Sáez, Marc Pedrosa Aragon, Lizza Maria Macorigh Mantilla, Elisabet Deig Comerma, Julia Gutierrez Sanjuan, Rodrigo Alonso Navarro, Oscar Del Rio Perez, Silvia Valero Rovira, Marta Navarro Vilasaró (Sabadell, Spain)
P179	**Virological and immunological outcomes in people living with HIV and disabilities: determinants from a multicenter study in China** Lijun Xu, Ziqing Yuan, Yu He, Ke Hong, Zhen Tang, Jinchun Shi, Li Wang, Guangyong Xu (Hangzhou, China)
P180	**No significant sex differences in antiretroviral treatment among ageing people living with HIV – results from the NONNA study** Oliver Schmidt-Radde, Markus Bickel, Pavel Khaykin, Gundolf Schuettfort, Christoph Stephan, Annette Haberl (Frankfurt am Main, Germany)
P181	**The burden of copies: a retrospective study of very low-level viremia in people living with HIV** Carolina Inacio Santos, Margarida Veloso, Marta Ribeiro, Sandra Mendes Fernandes, Ana Isabel Duarte, Isabel Diogo, Inês Costa, Fátima Gonçalves, Joaquim Cabanas, João Vaz Alves, Perpétua Gomes, Ana Cláudia Miranda (Lisbon, Portugal)
Treatment Strategies: Rapid ART initiation	
P182	**Nurse-directed same-day initiation of cART in persons with a new HIV diagnosis** Jessica S van der Mannen, Maaike Kok, Gijs Geerders, Narda van der Meche, Saskia ME Vrouenraets, Ineke WEM Schouten, Marieke JA de Regt, Daoud Ait Moha, Kees Brinkman, on behalf of HIV team OLVG (Amsterdam, Netherlands)
P183	**Comparison of dual and triple integrase inhibitor-based regimens toward the undetectable = untransmittable target** Melike Kaya Kaptan, Alper Gündüz, Okan Derin, Gözde Kuran, Ece Demirkırkan, Yusuf Yiğit, Esma Kaya Beyendi, Berna Demirok, Özlem Gül, Gizem Çal, Nuran Karabulut, Meliha Meriç Koç, Dilek Yıldız Sevgi, Özlem Altuntaş Aydın (İstanbul, Türkiye)
P184	**Real-world treatment pattern changes and time to virological suppression among people living with HIV in China** Hanxi Zhang, Hongxin Zhao, Lijun Sun, Jianhua Yu, Fujie Zhang (Beijing, China)
P185	**Effectiveness of DTG/3TC rapid initiation in treatment-naïve people living with HIV in Kuwait: a real-world cohort study** Osama Ali Ahmad Albaksami, Essam Mohamed Ali Elhabbak, Ahlam Mohamed Hafez Mohamed Abdalla, Roy Thampy Cherian, Hassan Fathy Sayed Abdelaal, Ibrahim Ashour Hamed Hassan, Evelina Zimovetz, Averyan Vasylyev, Hani Wali (Al Jahra, Kuwait)
P186	**Delayed rapid antiretroviral therapy initiation and its sociodemographic and clinical correlates: a secondary analysis of the ASAP study in Montreal, Canada** Moustafa Laymouna, Kim Engler, David Lessard, Serge Vicente, Sean Yaphe, Joseph Cox, Nadine Kronfli, Jean-Pierre Routy, Joel Ishak, Alexandra Hamel, Marina Klein, Alexandra De Pokomandy, Cecilia T Costiniuk, Kathy Nodzynski, Bertrand Lebouché (Montreal, Canada)

Scientific Posters

Treatment Strategies: Rapid ART initiation (continued)

P187	**SWIFT: start with immediate first-line therapy – time to viral suppression, baseline immunovirologic status and retention after rapid ART initiation at a Toronto community sexual health clinic** Kevin Woodward, Tim Guimond, Hommood Alrowais, Victor Monroy, Lucas Gergyek (Toronto, Canada)
P188	**Rapid HIV care linkage in a no-cost testing setting** Heather Alejandro, Michael Greathouse (Phoenix, AZ, USA)
P189	**Same-day B/F/TAF re-initiation after NNRTI-based ART discontinuation in China: baseline resistance and 24-week effectiveness** Yan Zhao, Yuan Guan, Hongxin Zhao, Linghua Li, Jun Liu, Juan Jin, Xia Li, Yaokai Chen, Yun He, Jiahua Qiao (Beijing, China)
P190	**Indirect comparison of the efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir/lamivudine for first-line therapy in a rapid-initiation setting: the BICNOW and DOLAVI clinical trial** Carmen Hidalgo-Tenorio, Sergio Sequera, Rosario Javier Martinez, Mar Rivero, Coral Garcia-Vallecillos, on behalf of BIC-NOW Group (Granada, Spain)
P191	**Rapid ART initiation and early retention among newly diagnosed people living with HIV: a real-world cohort in Taiwan** Hsin-Yen Ku, Na-Lee Sun, Shu-Ying Chang, Mei-Hui Lin, Shan-wen Chi, Yu-Wen Lin, Teng-Chun Wang, Chuan Pi, Shu-Yuan Li, Jui-Hsuan Yang, Cheng-Pun Chen, Chien-Yu Cheng, Shu-Hsing Cheng (Taoyuan City, Taiwan)
P192	**One day, one week: decoding the optimal ART start timing in people with HIV in the real-world setting** Giulia Micheli, Alessandro Caioli, Rozenn Esvan, Alessandro Giacinta, Virginia Barchi, Damiano Farinacci, Rebecca Jo Steiner, Neva Braccialarghe, Arianna Forniti, Eugenio Nelson Cavallari, Isabella Abbate, Lavinia Fabeni, Gabriella Rozera, Enrico Girardi, Fabrizio Maggi, Andrea Antinori, Valentina Mazzotta (Rome, Italy)

Treatment Strategies: Adherence

P193	**Comparable virologic outcomes across adherence levels with DTG/3TC and BIC/FTC/TAF in adults initiating ART: week 48 results from VOGUE** Karine Lacombe, Melchor Jaume, Gustavo Lopardo, Kehui Wang, Ruolan Wang, Adelaide Jewell, Emilie Elliot, Rebecca Borsi, Julie Priest, Michelle Kisare, Piotr Budnik, Jean van Wyk (Paris, France)
P194	**Superior long-term real-world adherence and persistence with long-acting cabotegravir+rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV in the US: the OPTIMIZE study** Andrew P Brogan, Maral DerSarkissian, Catherine Nguyen, Megan Pinaire, Emily Reichert, Qingyi Cai, Mark Lewandowski, Shana Walko, Ian Jacob, Megan Dominguez, Gregory Huhn (Durham, NC, USA)
P195	**Defects in the HIV 5'-leader may help to differentiate active replication from non-suppressible low-level viremia** Frank Wiesmann, Patrick Braun, Sarah Ritter, Jona-Lukas Bittner, Daniel Beer, Heribert Knechten (Aachen, Germany)
P196	**ART forgiveness: redefining PDC benchmarks against transient viraemia and confirmed virological failure in an INSTI era cohort** Beatrice Bragato, Francesco Vladimiro Segala, Daniele Mengato, Lolita Sasset, Eleonora Vania, Davide Leoni, Samuele Gardin, Anna Ferrari, Giacomo Berti, Annamaria Cattelan (Padua, Italy)

Scientific Posters

Treatment Strategies: Adherence (continued)

P197	**Use of an adapted pre-consultation adherence screener to identify behavioural barriers in HIV treatment and prevention services across the UK and Ireland** Nicola Galbraith, Jordan McLaren, Sarah Edwards, Kathryn Carroll, Omoyemi Daramola, John Weinman (London, UK)
P198	**Abstract withdrawn**
P199	**Decreased mood and non-medical reasons as main causes for ART interruption – results from a survey among people with HIV in a single centre study in Poland** Dagny Krankowska, Ewa Siwak, Tomasz Mikuła, Agnieszka Lembas, Mariusz Sapuła, Aneta Cybula, Wiktoria Gajek-Flanczewska, Sebastian Flanczewski, Alicja Wiercińska-Drapało (Warsaw, Poland)
P200	**Anxiety, depression and adherence to antiretroviral therapy in people living with HIV** Marco Antonio Lopez Hernandez, Ericka Denise Bustos Angel (Mexico City, Mexico)
P201	**Patterns of care interruption and re-engagement in HIV care across the COVID-19 pandemic eras** Kyoko Yoshida, Ryoko Sekiya, Seowoong Jung, Masaru Tanaka, Taiichiro Kobayashi, Kazuaki Fukushima, Keishiro Yajima, Akifumi Imamura (Tokyo, Japan)
P202	**Changes in pattern of adherence to oral antiretrovirals by pharmacy refill in a large cohort of people with HIV over 11 years** Alessandra AM Pagani, Ludovica Mazzoleni, Francesca Facciolo, Michela Franzin, Roberto Teocchi, Laura Comi, Federica Borghi, Fulvio Crippa, Diego Ripamonti (Bergamo, Italy)
P203	**Community HERO treatment survey: experiences of people with HIV in Taiwan** Yun-Chung Lu, Kris Mar, Marcel Dams, Nomfundo Eland, Maureen Owino, Carlos Saucedo, Josep Mallolas, Larkin Callaghan, Michael Bogart, Neia Prata Menezes, MengJu Tsai, Connie Kim (Foster City, CA, USA)
P204	**Retaining adolescents with HIV in care through targeted youth camps in Kisumu, Kenya** Annabel Kokeyo (Kisumu, Kenya)
P205	**Enhancing adherence, emotional well-being and psychological resilience: exploring expressive art therapy for children and adolescents affected by HIV** Annabel Kokeyo (Kisumu, Kenya)
P206	**High acceptability and adherence in a pilot randomized controlled trial of an antiretroviral therapy real-time electronic adherence monitoring and response intervention among African American men who have sex with men with HIV** Mark Dworkin, Sierra Upton, Katherine Bezaitis, Autumn Smith, Corina Wagner, Elle Martell, Michael Reh, Kara Herrera, Li Liu, Jessica Haberer (Chicago, IL, USA)
P207	**When HIV becomes chronic but never ordinary: experiences of living with HIV and disengagement from care** Tea Nynne Sanders, Susanne Dam Nielsen, Susanne Kriegel Pedersen, Selina Kikkenborg Berg, Ole Kirk, Malene Missel (Copenhagen, Denmark)
P208	**PrEP engagement among underserved cisgender women in the UK: results from the PrEP-position mixed-methods study** Vian Rajabzadeh, Sophie Strachan, Melanie Smuk, Nishat Halim, Caro Camargo, Chloé Pasin, Megan Devonald, Anqa Awan, Taranjit Chana, Kelsea Delatango, Vimbai Mandaza, Pamela Menzies-Banton, Zoch Nwaosu, Juddy Otti, Kyle Ring, PrEP-Position Steering Group Member, Angelina Namiba, Vanessa Apea, Sara Paparini, Chloe Orkin (London, UK)

Scientific Posters

Clinical management considerations: women

P209	**Longitudinal immune and inflammatory adaptations during pregnancy in women with HIV** Sandra Chaudron, Marius Zeeb, Chloé Pasin, Sara Schütz, Mailin Waldecker, Julia Notter, Anna Hachfeld, Paolo Paioni, Annalisa Marinosci, Matthias Cavassini, Roger Kouyos, Ladina Vonzun, Irene A Abela, on behalf of Swiss HIV Cohort Study (Zurich, Switzerland)
P210	**Gender-specific determinants of frailty among people with HIV aged ≥ 50 years (Over50 cohort): evidence for a multidimensional vulnerability phenotype in women with HIV** Patricia Echeverría, Jordi Puig, Ana Martínez, Itziar Arrieta, Isabel Arnau, Lucía Bailón, Carla Estany, Begoña Lemos, Anna Bonjoch, Robert Güerri, Eugenia e (Badalona, Spain)
P211	**High burden of dyslipidaemia and hypertension despite virological control in women living with HIV over 50 years** Joana Marinho Silva, Filipe Medeiros, Hugo Graça, Luísa Lopes, Cristina Valente (Coimbra, Portugal)
P212	**Late antenatal booking among women living with HIV in England: findings from national surveillance data 2020–2024** Helen Peters, Laura Byrne, Rebecca Sconza, Kate Francis, Yvonne Gilleece, Claire Thorne (London, UK)
P213	**Treatment persistence and reasons for discontinuation of long-acting cabotegravir/rilpivirine among women living with HIV: a real-world multicentre cohort study** Layla Pagnucco, Maria Vittoria Cossu, Maddalena Matone, Annalisa Bergna, Aurora Pozzi, Agostino Riva, Roberto Gulminetti (Pavia, Italy)
P214	**Pregnancy outcomes following dolutegravir/lamivudine two-drug therapy in women living with HIV: a real-world case series** Layla Pagnucco, Marianna Roccio, Valentina Zuccaro, Laura Maiocchi, Raffaele Bruno, Grazia Bossi, Alessandro Borghesi, Roberto Gulminetti (Pavia, Italy)
P215	**Abstract withdrawn**
P216	**Physical and psychosocial vulnerability among women ageing with HIV** Andronikos Spyrou, Emmanouela Kalogianni, Michalis Ploumidis, Georgios Adamis, Myrto Astriti (Athens, Greece)
P217	**Community HERO Treatment Survey: understanding drivers of treatment satisfaction and adherence among cis women with HIV** Alissar Moussallem, Xavier Guillaume, Marcel Dams, Nomfundo Eland, Maureen Owino, Carlos Saucedo, Yun-Chung Lu, Josep Mallolas, Amina Omri, Larkin Callaghan, Michael Bogart, Neia Prata Menezes, Connie Kim (Foster City, CA, USA)
P218	**Menopause-associated metabolic changes in women living with HIV switching to bictegravir/emtricitabine/tenofovir alafenamide: a real-world analysis** Vito Speciale, Andrea Gasperin, Giulia Mancarella, Daniela Di Trento, Lorenzo Ansaldo, Margherita De Masi, Lorenzo Mazzanti, Livia Bresciani, Salvatore Iaquinandi, Serena Vita, Anna Carraro, Valeria Filippi, Caterina Pasquazzi, Cosmo Del Borgo, Miriam Lichtner, Raffaella Marocco (Rome, Italy)
P219	**Women living with HIV and menopause status: real world evaluation of ART efficacy, metabolic profiles and comorbidities** Giuseppe Nunnari, Serena Spampinato, Marta Scifo, Dalida Bivona andrea Marino, Bruno Cacopardo, Alessandro Franzo, Roberto Bruno, Nunziatina Villari, Benedetto Maurizio Celesia, Paolo Fagone, Grazia Scuderi (Catania, Italy)
P220	**Kidney function in women aged ≥ 50 years living with HIV: a cross-sectional analysis of a Portuguese cohort** Hugo Graça, Filipe Medeiros, Luísa Lopes, Joana Marinho, Margarida Prata, Cristina Valente (Coimbra, Portugal)

Scientific Posters

Clinical management considerations: women (continued)	
P221	**Long-term effectiveness and safety of bictegravir/tenofovir alafenamide/emtricitabine in women living with HIV in Argentina** Cinthia Lamaizon, Diego Cecchini, Gaston Copertari, Martin Brizuela, Brenda Bacelar, Macarena Roel, Edgardo Bottaro, Isabel Cassetti (Buenos Aires, Argentina)
P222	**Age-related differences in virological suppression among women living with HIV receiving antiretroviral therapy: a real-world Brazilian cohort** Pietra Stanicki, Karen Ingrid Tasca, Alexandre Naime Barbosa (São Paulo, Brazil)
Clinical management considerations: late presenters	
P223	**Late presentation and advanced HIV disease in Latin America after the COVID-19 pandemic: a multi-country analysis** María Greco, Pedro Zitko, Carlos Beltrán, Isabel Cassetti, Ricardo Alcantar Morales, Ana Arauz, Lilian Astocondor, Jesús Dawaher, Idaura González, Cinthia Lamaizón, Eric Delgado, Mónica Mantilla, Alejandro Afani, Ernesto Martínez Buitrago, Rodolfo Pinzón Meza, Javier Ricart, Ana Vega Calderón, David Forero, Jenny Dreyfus, Javier Mota, Leonardo Arévalo, on behalf of Latin American HIV Workshop Study Group (La Plata, Argentina)
P224	**Clinical complexity, opportunistic infections and determinants of in-hospital mortality in young adults living with perinatally acquired HIV in a reference public centre in Argentina** Javier José Ricart, Ana de Prada, Dana Mijalovsky, Laura Macías Moreno, Cintia Giomi, Nicolas Nahum, Matías Gastón Pérez, Matías Enzenhofer, Luis De Carolis, Natalia Soledad Vittar, Graciana Cárdenas, Gustavo Bruni, Sofía Bauer, Florencia Villafañe, Emilse Vázquez, Rubén Solari (Buenos Aires, Argentina)
P225	**Risk of not achieving virological suppression by week 48 in people with HIV starting first-line therapy: differences by calendar period (2016–2025) and contributing factors** Manuela Colafigli, Giuseppe Lapadula, Franco Maggiolo, Samuel Lazzarin, Lucia Taramasso, Giulia Micheli, Simona Di Giambenedetto, Francesca Ceccherini-Silberstein, Antonella Castagna, Sergio Lo Caputo, Valentina Mazzotta andrea Antinori, Cristina Mussini, Alessandro Cozzi-Lepri, on behalf of ICONA Cohort Study Group (Aosta, Italy)
P226	**Determinants of suboptimal immune recovery despite viral suppression among people living with HIV: the ACTHIV-IST cohort of advanced presenters** Ahsen Oncul, Okan Derin, Sibel Yıldız Kaya, Alper Gündüz, İnci Yılmaz Nakir, Bilgul Mete, Özlem Altuntaş Aydın, Hindirin Takak, Ahmet Doğukan Bayrak, Meliha Meriç Koç, Esra Zerdali, Dilek Yildiz Sevgi, Fehmi Tabak (Istanbul, Türkiye)
P227	**Routine lumbar puncture for asymptomatic cryptococcal antigenemia in people living with HIV: should we be more selective?** Daniel Toscano, Inês Reis Luís, Patrícia Pacheco, Rita Patrocínio Jesus (Lisbon, Portugal)
P228	**New HIV diagnoses at a Portuguese tertiary care centre: does migrant status impact late presentation and 1-year outcomes?** Ana Jorge Martins, Rúben Carvalho, Joana Marinho, Tiago Neves, Luísa Cristina, Filipe Medeiros, Cristina Valente (Coimbra, Portugal)
P229	**Dual drug regimens simplification for late presenters: real-life data from 2016-2025 at Legnano Hospital, Italy** Maria Paola Bissanti, Dario Bernacchia, Gabriele Pagani, Maurizio Mena, Michela Rigoni, Marianna Ticozzelli, Andrea Mulekela Tshishimbi, Stefano Rusconi (Milan, Italy)

Scientific Posters

Clinical management considerations: late presenters (continued)

P230	**Advanced HIV disease among newly diagnosed people living with HIV in 39 health facilities in Enugu State, Nigeria, 2023–2025** Anuli Oyeka, Peter Chiagorom, Ita Egharevba, Elizabeth Marcus, Ogechi Ezeobi, Henrietta Ozobodo, Chukwudi Okwor, Fabian Bassey, Ifeoma Tony-Monye, Eugene Onu, Victor Enejoh, Mabwe Kubwa, Lawrencia Agur, Dorcas Magbadelo, Young Oluokun, Amana Effiong, John Oko, Abaniwonnda Sulaiman, Chukwudi Onwuchekwa, Olufemi Oke, Flora Nwagagbo, Dennis Onotu (Abuja, Nigeria)
P231	**Clinical and epidemiological profile of people newly diagnosed with HIV in a Portuguese infectious diseases department (2019–2025)** Mariana Azevedo, Estela Sousa, Natália Buruian, Carmela Piñeiro, Rosário Serrão, Lurdes Santos (Porto, Portugal)

Clinical management considerations: transgender people

P232	**Integrating HIV prevention, same-day antiretroviral therapy initiation, primary care and gender-affirming services to support engagement in care among transgender people** Darya Fridman (Las Vegas, NV, USA)
P233	**Impact of advanced HIV disease on mortality among transgender women: a 13-year cohort study in Buenos Aires, Argentina** Mauro Bertolini, José Ángel Barletta, María José Rolón (Buenos Aires, Argentina)
P234	**Cabotegravir rilpivirine LA treatment for transgender women living with HIV** Valentina Isernia, Marc Digumber, Elisabet Costa I Otal, Florence Michard, Gerard Castanedo, Antoine Bachelard, Charlotte Charpentier, Gilles Peytavin, Jade Ghosn (Paris, France)
P235	**Impact of antiretroviral therapy on virologic failure and loss to follow-up among transgender women and travestis in São Paulo, Brazil: data from the TransBordar study** Maria Felipe Faustino de Medeiros, Victória Spínola Duarte de Oliveira, Camila Albuquerque de Moraes, Cristiane Pereira, Camilla Ferreira Santos, Cinthia Dellaqua, Giovanna Haimowski, Josiane Vitor de Souza Oliveira, Dyemison Pinheiro da Silva, Ricardo Augusto de Braga Castro, Priscilla Faria Pereira, Natalia Mercedes Cabral Amdi, Luciene Arrifano da Silva, Mylva Fonsi, Roberta Schiavon Nogueira, José Valdez Ramalho Madruga, Vinicius de Paula dos Anjos, Ana Caroline Coutinho Iglessias, on behalf of TransBordar Study Group (São Paulo, Brazil)
P236	**Sociodemographic profile and risk factors for loss to follow-up and virological failure among transfeminine people living with HIV: TransBordar – a retrospective study in São Paulo, Brazil** Maria Felipe Faustino de Medeiros, Victória Spínola Duarte de Oliveira, Camila Albuquerque de Moraes, Cristiane Pereira, Camilla Ferreira Santos, Cinthia Dellaqua, Giovanna Haimowski, Josiane Vitor de Souza Oliveira, Dyemison Pinheiro da Silva, Priscilla Faria Pereira, Natalia Mercedes Cabral Amdi, Luciene Arrifano da Silva, Lucas de Souza Loureiro Abbud Santos, Ricardo Augusto de Braga Castro, Roberta Schiavon Nogueira, José Valdez Ramalho Madruga, Vinicius de Paula dos Anjos, Ana Caroline Coutinho Iglessias, on behalf of TransBordar Study Group (São Paulo, Brazil)
P237	**PrEP modality and delivery setting preferences for transgender and nonbinary people in the UK: the PrEP-Position mixed-methods study** Vian Rajabzadeh, Sophie Strachan, Melanie Smuk, Nishat Halim, Caro Camargo, Chloé Pasin, Megan Devonald, Anqa Awan, Taranjit Chana, Kelsea Delatango, Vimbai Mandaza, Pamela Menzies-Banton, Zoch Nwaosu, Juddy Otti, Kyle Ring, PrEP-Position Steering Group Member, Angelina Namiba, Vanessa Apea, Sara Paparini, Chloe Orkin (London, UK)

Scientific Posters

Clinical management considerations: other

P238	**Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) tablet for oral suspension (TOS) in children and infants aged ≥ 1 month, weighing 3 to < 25 kg: week 48 outcomes** Natella Rakhmanina, Eva Natukunda, Peter Elyanu, Jeanne Coetzee, Samantha Fry, Elizabeth Hellström, Umesh Lalloo, Afaaf Liberty, Kathleen McGann, Carina A Rodriguez, Athira Sudhakaran, Kate Anteyi, Vinicius A Vieira, Kathryn Kersey, Flavia Matovu Kiweewa (Washington, DC, USA)
P239	**Virological outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) through week 48 in children and infants aged ≥ 1 month and weighing ≥ 3 to < 25kg** Natella Rakhmanina, Eva Natukunda, Jeanne Coetzee, Peter Elyanu, Samantha Fry, Elizabeth Hellström, Umesh Lalloo, Afaaf Liberty, Carina A Rodriguez, Kristen Andreatta, Jing Nui, Athira Sudhakaran, Vinicius A Vieira, Flavia Matovu Kiweewa (Washington, DC, USA)
P240	**Prescription medication use, comorbidity burden and drug-drug interaction potential among people with HIV in a large US claims database (2024)** Andrew Weber, Linda Grasfeder, Harini Vadlamudi, George Mu, Palak Phansalkar, Aimee Metzner, Justin Hay, Mahmoud Afifi, Joseph Polli (Durham, NC, USA)
P241	**Characteristics of children and young people newly presenting to paediatric HIV services in England: 2023–2025** Alexandra David, Alasdair Bamford, Kate Francis, Charlie Gorman, Anna Kafkalia, Claire Thorne, Helen Peters (London, UK)
P242	**Age-related decline in virological suppression among adolescents living with HIV: increasing rates of viral load ≥ 1,000 copies/mL from early to late adolescence** Serhii Riabokon, Diana Shevchenko, Olena Samsonova, Larysa Hetman (Kyiv, Ukraine)
P243	**A study on depression and stress behaviours in people living with HIV after three years of harm reduction intervention for chemsex** Na-Lee Sun, Chien-Yu Cheng, Shu-Hsing Cheng (Taoyuan, Taiwan)
P244	**Who suppresses faster? Exploring time to viral suppression among school going children and adolescents living with HIV in Kampala, Uganda: a survival analysis** Gertrude Ddamulira Namale, Patrick Kazooba, Emmanuel Sendaula, Francis Wasswa, Hilda Achayo, Joseph Lwembawo, Josephine Kaleebi (Kampala, Uganda)
P245	**Abstract withdrawn**
P246	**Cabotegravir and rilpivirine injectable therapy with concomitant tuberculosis preventative treatment (TPT) consisting of rifapentine/isoniazid as 1HP** Jinell White, Brandon Christensen, Morgan Lahl, M John Gill (AB, Canada)

Cure/post-treatment control

P247	**Context-dependent innate immune reprogramming after BCG vaccination in treated HIV-1 infection** Cedric Dolle, Terence Tutumlu, Lena Bartl, Baptiste Depouilly, Doris Russenberger, Marius Zeeb, Katharina Kusejko, Emily West, Dominique Braun, Magdalena Schwarzmüller, Baptiste Elie, Alexandra Trkola, Huldrych Guenthard, Johannes Nemeth (Zurich, Switzerland)
P248	**Abstract withdrawn**
P249	**Gut microbiota signatures associated with incomplete CD4 recovery in antiretroviral therapy-treated people living with HIV** Aycan Gundogdu, Nermin Safarova, Buket Banu Ozkan, Özkan Ufuk Nalbantoglu, Aysegul Ulu Kilic (Kayseri, Türkiye)

Scientific Posters

Cure/post-treatment control (continued)

P250	**Towards NGS-based characterisation of the HIV-1 5' leader region in non-suppressible viraemia** Marta Illescas-López, Paloma Muñoz-Báez, Ana Fuentes, Adolfo de Salazar, Federico García (Granada, Spain)
P251	**Identification of the molecular target and mechanism of action of EK-16A, a natural HIV-1 latency-reversing agent derived from Euphorbia kansui** Jingna Xun, Xinyi Yang, Yinzhong Shen, Huanzhang Zhu (Shanghai, China)
P252	**From "what might have been" to "what could be": counterfactuals in HIV cure research** Mark Janse, Kai Jonas, Casper Rokx (Rotterdam, Netherlands)
P253	**Dynamics of intact and total HIV-1 DNA-reservoirs in relation to plasma viral load levels** David Mwangi, Malik Prentice, Hai-Tam Lam, Robert Ehret, Martin Obermeier (Berlin, Germany)
P254	**CD4/CD8 ratio recovery versus persistence of inversion in virologically suppressed people with HIV: a 20-year single-centre cohort** Daniel Elbirt, Ramon Cohen, Laliv Kadar, Ilan Asher, Shira Rosenberg-Bezalel, Keren Mahlab-Guri, Shay Nemet (Rehovot, Israel)

Opportunistic infections and AIDS-defining cancers

P255	**Prevalent cytomegalovirus (CMV) disease among ART-naïve people with HIV: temporal trends and persistent mortality in the ICONA cohort, 1997–2024** Annalisa Mondi, Nicolò Lentini, Serena Vita, Andrea Giacomelli, Roberta Gagliardini, Nicoletta Bobbio, Giordano Madeddu, Annalisa Saracino, Elisabetta Teti, Alessandra Rodanò, Giulia Marchetti, Cristina Mussini, Antonella D'Arminio Monforte, Andrea Antinori, Miriam Lichtner, on behalf of ICONA Cohort Study Group (Rome, Italy)
P256	**Abstract withdrawn**
P257	**Clinical and immunological characteristics of people living with HIV who developed immune reconstitution inflammatory syndrome** Ana Salvador Rodríguez, Marianela Ciudad Sañudo (Madrid, Spain)
P258	**Burden of advanced HIV disease and one-year outcomes among people re-engaging in HIV care at a public hospital in Argentina** Ana Rodriguez, Victoria Pinto, Valentina Nuri Balbi Rocca, Eugenia Pia Sobrado, Lucia Nannini, Mariana Ariadna Paolini, Francisco Martin Ferreira Monteiro, Julian Vega, Veronica Azul Benseñor, Alicia Sisto, Maria Jose Rolon, Martín Jaume (Buenos Aires, Argentina)
P259	**Abstract withdrawn**
P260	**Lessons from the nineties: sight threatening CMV retinitis as part of an immune reconstitution inflammatory syndrome (IRIS) in a patient who is allergic to valganciclovir** Emily Cullis, Delia-Mercedes Bianco, Kala Gopalakrishnan, Lorraine Cullen, Kate Adams, Mariya Molai (Kingston upon Hull, UK)
P261	**Neglected killers, shared solutions: talaromycosis in advanced HIV disease and invasive fungal infections in diabetic patients – a case series and the case for integrated fungal diagnostic and treatment access in resource-limited Indonesia** Yusuf Aulia Rahman, Lina Herliyana, Otta Nur Kirana, M Labib MY Bima, Lukman Pura (Bandar Lampung, Indonesia)
P262	**The impact of R-CHOP-based immunochemotherapy on HIV tropism, quasi-species and viral reservoir in patients with AIDS-related lymphoma** Biao Zhu, Ye Xiong, Xiaorong Peng (Hangzhou, China)

Scientific Posters

Clinical pharmacology

P263	**Transient immediate systemic side effects after long-acting cabotegravir/rilpivirine injections: a 5-year cohort study** Laurent Hocqueloux, Daniela Pires Roteia, Sandra Pallay, Aurélie Theillay, Guillaume Beraud, Julie Bois, Thierry Prazuck (Orléans, France)
P264	**Body weight changes, rilpivirine and cabotegravir trough concentrations in people living with HIV receiving long-acting injectable antiretroviral therapy in southern Taiwan** Hung-Chin Tsai, Pei-Yun Chou, Hui-Min Chang (Kaohsiung, Taiwan)
P265	**Phase 1 study to investigate the absorption, metabolism and excretion of ulonivirine, a non-nucleoside reverse transcriptase inhibitor, in adults without HIV** Gillian Gillespie, Michelle Pham, Makeda Robinson, Marissa Vavrek, Yuexia Liang, Yiran Huang, Kimberly Thomas, Yang Liu, Jon Meiman, Jesse C Nussbaum (Rahway, NJ, USA)
P266	**Population pharmacokinetic modelling of plasma and intracellular bictegravir in people living with HIV** Emmanuel Niyigena, Julien De Greef, Nadtha Panin, Jean Cyr Yombi, Erwin Dreesen, Leïla Belkhir, Vincent Haufroid, Laure Elens (Brussels, Belgium)
P267	**Characterisation of the clinical drug–drug interaction profile of VH4524184 (VH-184), a third-generation integrase strand transfer inhibitor** Eileen Castronova, Jon Collins, Fiona Halliday, Alex Ballesteros-Perez, Riya Moodley, Luise Rogg, Jorge Villacian, Hyunmoon Back (Rahway, NJ, USA)
P268	**Phase 1 study to evaluate the effect of a single supratherapeutic dose of MK-8527 on QTc interval prolongation in healthy adults** Russ P Carstens, Yash Kapoor, Arinjita Bhattacharyya, Bhavna Kantesaria, Graigory C Garrett, Peter Addo, Ryan Vargo, Michael Hassman, Jesse C Nussbaum (Marlton, NJ, USA)
P269	**Abstract withdrawn**
P270	**Subtherapeutic cabotegravir and/or rilpivirine plasma concentrations after long-acting intramuscular injections: experience from a nationwide TDM service** David Burger, Anne Kamphuis, Tom Jacobs, Piter Oosterhof, Lindsey Te Brake, Ralf Stemkens, Godelief Janssen-van den Hurk, Nynke Jager, Roger Bruggemann, Rob Aarnoutse (Nijmegen, Netherlands)
P271	**Clinical consequences of the "pharmacokinetic tail" after discontinuation of long-acting cabotegravir/rilpivirine: three illustrative cases** David Burger, Marieke De Regt, Gijs Geerders, Thijs Van de Laar, Jacobien Hoogerwerf, Martine De Haan, Piter Oosterhof (Nijmegen, Netherlands)
P272	**Changes in body weight during tenofovir prodrug exposure in mice: implications for interpreting weight gain after switching from TDF to TAF** Kensuke Abe, Emiko Sato, Taku Obara, Satomi Kamio, Toshihiro Ito, Nobuyuki Takahashi (Sendai, Japan)
P273	**Association of UGT1A1 and CYP3A5 genetic polymorphisms on plasma concentrations of cabotegravir and rilpivirine following long-acting injectable administration in Japanese HIV-1-infected patients** Hiroki Yagura, Takao Nakauchi, Ayumi Hisari, Ayano Fujiwara, Keiji Konishi, Kazuyuki Hirota, Takashi Ueji, Yasuharu Nishida, Minoru Kawai, Tomoko Uehira, Takuma Shirasaka, Jun Komano, Dai Watanabe (Osaka, Japan)
P274	**Treatment-emergent bictegravir resistance following nasogastric administration of bictegravir/emtricitabine/tenofovir alafenamide in a patient with advanced AIDS and cerebral toxoplasmosis** David Kleinman, Stephen Shafran, Pam Nickel, Conar O'Neil (AB, Canada)

Scientific Posters

Community-based treatment and prevention initiatives, including primary care screening

P275	**Creating the conditions for shared decision-making: perspectives of people living with HIV and HIV support organizations across 29 countries** Ama Appiah, Brent Allan, Garry Brough, Erika Castellanos, Daniela Rojas Castro, W David Hardy, Kota Iwahashi, Sindy Mbudwini, Marta McBritton, Mary Ndungu, Annette Piecha, Bruce Richman, Mercy Shibemba, Dainielle Fox, Shaun Mellors, Vilma Vega, Nneka Nwokolo, Emily Carr, Rickesh Patel (London, UK)
P276	**Beyond the primary provider: peer support, U=U communication and HIV treatment outcomes in global care settings** Ama Appiah, Brent Allan, Garry Brough, Erika Castellanos, Daniela Rojas Castro, W David Hardy, Kota Iwahashi, Sindy Mbudwini, Marta McBritton, Mary Ndungu, Annette Piecha, Bruce Richman, Mercy Shibemba, Dainielle Fox, Shaun Mellors, Vilma Vega, Nneka Nwokolo, Emily Carr, Rickesh Patel (London, UK)
P277	**Living with HIV across the life course: gender and age differences in stigma, sexual health communication and care needs in 29 countries** Ama Appiah, Brent Allan, Garry Brough, Erika Castellanos, Daniela Rojas Castro, W David Hardy, Kota Iwahashi, Sindy Mbudwini, Marta McBritton, Mary Ndungu, Annette Piecha, Bruce Richman, Mercy Shibemba, Dainielle Fox, Shaun Mellors, Vilma Vega, Nneka Nwokolo, Emily Carr, Rickesh Patel (London, UK)
P278	**Reach and HIV outcomes among women who use drugs in Abuja, Nigeria: evidence from a gender-responsive community harm reduction programme, 2024–2026** Ifeanyi Ngwoke, Oluwafisayo Alao-Amiola, Boluwatife Owoyemi, Adeolu Adebiyi (Abuja, Nigeria)
P279	**Feasibility of delivering long-acting cabotegravir as PrEP beyond sexual health services – a mixed methods study** Rosalie Hayes, Chloe Orkin, Melanie Smuk, Nishat Halim, Sara Paparini (London, UK)
P280	**Bridging the gap between HIV vulnerability and prevention: risk perception and PrEP engagement among cisgender women, accessing a community-based centre in Italy** Liudmila Nekrasova, Lorenzo Cavallero, Enrico Caruso, Roberto Repossi, Donatello Zagato, Ivan Gotti, Paolo Russo, Pietro Vinti, Davide Moschese, Valentina Iannone, Chiara Fusetti, Roberto Rossotti, Massimo Cernuschi, Nicoletta Frattini (Milan, Italy)
P281	**Viral suppression and retention in care for non-suppressing children and adolescents living with HIV enrolled in ICSDM in East Central Africa** Ibrahim Twinomujuni (Kampala, Uganda)
P282	**Emergency department (ED) bundled HIV, HBV and HCV screening using residual blood samples in Italy: challenges and opportunities** Federico Cecilia, Martina Leone, Sara Ciarpaglini, Enrico Perugini, Diletta Meloni, Livia Benedetti, Alfredo Giovannelli, Martina Pelagalli, Flaminia Tomassetti, Drieda Zace andrea Di Lorenzo, Jacopo Maria Legramante, Carla Paganelli, Vincenzo Malagnino, Sergio Bernardini, Massimo Pieri, Loredana Sarmati, Anna Maria Geretti, on behalf of PROGRESSO-T Study Team (Rome, Italy)
P283	**Peer-led territorial outreach is associated with higher screening uptake among young candidates for long-acting PrEP research in São Paulo, Brazil** Vinicius Silva, Lucas Ramos, Camila Moraes, Aline Cano, Giovanna Haimowski, Camilla Ferreira, Fabíola Rocha, Pisci Bruja, Dyemison Silva, José Madruga, Roberta Nogueira (São Paulo, Brazil)
P284	**A case-manager-lead telephone call-back strategy substantially increases HIV testing coverage among patients diagnosed with sexually transmitted infections: a four-year single-centre analysis** Chia-Jui Yang, Chung-Yu Shih, Yin-Hsuan Chiang, Mao-Song Tsai (New Taipei City, Taiwan)

Scientific Posters

Community-based treatment and prevention initiatives, including primary care screening (continued)

P285	**Bundled, community-embedded HIV pre-exposure prophylaxis pathways for underserved groups: a multi-site quality improvement initiative** Jennifer Whetham, Luke Byrne, Emma Rutland, Elisabete Miranda, Marc Tweed, Emma Lock, Clare Lewandowski-Fowler-Porter, Kamran Khan, Vikki Pearce, Martyn Wood (Liverpool, UK)
P286	**A preliminary evaluation of the reimbursement application process for long-acting Injectable antiretroviral therapy among healthcare professionals in Taiwan** Na-Lee Sun, Shu-Hsing Cheng, Chien-Yu Cheng (Taoyuan, Taiwan)
P287	**Enhancing community-centred treatment, prevention and early screening strategies** Ronald Ondari, Sarah Nyaboke (Nairobi, Kenya)
P288	**Implementation of integrated HIV and viral hepatitis screening in a federally qualified health centre: a retrospective evaluation** Lamiya Hussain (Norcross, GA, USA)
P289	**Abstract withdrawn**
P290	**Have I taken enough preventive measures? A cross-sectional study related to HIV testing behaviour and associated factors among men who have sex with men in the Yogyakarta region, Indonesia** Dwi Kartika Rukmi, Dewi Nur Amannah, Novita Nirmalasari, Afi Lutfiyati (Sleman, Indonesia)
P291	**Group by time analyses of aligning sexual agreement behaviours with using HIV prevention and care strategies: pooled intervention exposure results from a digital HIV neutral intervention randomized controlled trial with adult, cisgender male couples** Jason Mitchell, Christofer Rodriguez, Amber Sophus, Zoran Bursac (Miami, FL, USA)
P292	**Abstract withdrawn**
P293	**A compact platform for decentralised HIV viral load and serological testing using small-volume blood samples** Tim Cummins, Ivan O'Connell, Anita Schuler, David McGuire, Moira McCarthy, Colin King, Paul Free, Xi Cao, Lorcan Walsh, John O'Driscoll, Kaylyn Oshaben, Margaret Aherne, John Walshe, Tara Dalton, Federico García, Ana Fuentes, Daniel H Appella, Brian O'Farrell (Cork, Ireland)
P294	**Abstract withdrawn**
P295	**Abstract withdrawn**
P296	**"Arrested because we help": psychological burden, demotivation and impact of arrests on men who have sex with men community counsellors in Dakar, Senegal – a mixed-methods study after the February 2026 media crisis** Élisabeth Kangou Diouf, Abdou Khoudia Diop (Dakar, Senegal)
P297	**Clinical outreach for Atlanta's unhoused – an opportunity to increase HIV detection and linkage through collaborative screening strategies** Victoria Brown, Julia Blackwell, Ian Fennell, Breanna Lathrop, Jennifer Mathew, Michael Gibson (Atlanta, GA, USA)
P298	**Abstract withdrawn**
P299	**Integrating HIV care, primary care and wrap-around services to support engagement in care in an LGBTQ+-centred community health setting** Darya Fridman (Las Vegas, NV, USA)

Scientific Posters

Public health strategies and options

P300	**The paradox of high coverage: persistent HCV reinfection in care-engaged men who have sex with men networks** Daniele Calzavara, Alessandro Giudo Soria, Roberto Rossotti, Nicoletta Policeck (Roma, Italy)
P301	**Long-term effectiveness of the quadrivalent HPV vaccine against anal dysplastic lesions in HIV-MSM from a phase IV RCT: a propensity score-matched post-RCT cohort follow-up study** Carmen Hidalgo, Saioa Igartua, Mohamed Omar, SamPedro Antonio, Javier Lopez Hidalgo, Jessica Ramirez Taboada (Granada, Spain)
P302	**The role of digital tools in facilitating PrEP uptake: a systematic review and meta-analysis** Victoria Tittle, Alejandro de Gea Grela, Andrea Perez Navarro, Sarah Fidler, Andrew Hill, Charlotte-Eve Short, Fiona Burns, Marta Boffito (London, UK)
P303	**The impact of migrant-inclusive policy in Botswana's universal HIV treatment programme: a retrospective analysis of the national HIV treatment programme data (2016–2022)** Patrick Mokgethi, Ontlametse T Choga, Wonderful T Choga, Dorcas Maruapula, Natasha O Moraka, Graceful Mulenga, Kesaobaka Molebatsi, Catherine K Koofhethile, Sununguko W Mpoloka, Tafireyi Marukutira, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)
P304	**Timing of HIV acquisition among migrants in the Netherlands** Ard van Sighem, Eline Op de Coul, Daniela Bezemer, Marc van der Valk, on behalf of ATHENA Observational HIV Cohort (Amsterdam, Netherlands)
P305	**Different viral load criteria to trigger resistance testing – implications for HIV programs in southern Africa** Niklaus D Labhardt, Anna Klicpera, Maren Röhl, Blaise Lukau, Lorena Urda, Giuliana Sanchez Samaniego, Moleboheng Mokebe, Lipontso Motaboli, Mosa M Monyake, Tapiwa Tarumbiswa, Irene Ayakaka, Jochen Ehmer, Roger D Kouyos, Gioia Wick, Tom Loosli, Richard Lessells, Jennifer Giandhari, Maria Selebalo, Nadine Tschumi, Jennifer A Brown (Basel, Switzerland)
P306	**Capturing mortality among people living with HIV across Europe: a comparison of routine surveillance data with an international cohort study** Bastian Neesgaard, Joanne Reekie, Teymur Noori, Erika Duffell, Disa Hansson, Anemarie Rinder Stengaard, Dorthe Raben, Lene Ryom Nielsen, Juliana Reyes-Urueña, on behalf of RESPOND and the EU/EEA HIV Networks (Copenhagen, Denmark)
P307	**HIV care cascade during the first year among people re-engaging in care** Ana Rodriguez, Victoria Pinto, Eugenia Pia Sobrado, Mariana Ariadna Paolini, Valentina Nuri Balbi Rocca, Julian Vega, Lucia Nannini, Francisco Martin Ferreira Monteiro, Veronica Azul Benseñor, Alicia Sisto, María José Rolon, Martín Jaume (Buenos Aires, Argentina)
P308	**Evaluating outcomes of indeterminate results in emergency department opt-out HIV testing** Anika Jayanth, Lauren Pereira-Greene, Mark Longman, Alex Comer, Rachel Thompson, Patrycja Puszkiewicz, Patrick French, Stuart Flanagan, Nadia Ahmed (London, UK)
P309	**To what extent does pol-based HIV-1 subtyping underestimate regional CRF and recombinant-complex diversity? A quantification of bias using COMET** Alexandria Williams, Virginie Mortier, Sonia Menon (Ghent, Belgium)
P310	**Beyond guidelines: a thematic synthesis of facilitators and barriers for embedding routine HIV testing into European hospitals** Klaske Vliegenthart-Jongbloed, Isabella Pepe Razzolini, Ciska Hoving, Winston van Druten, Sarah Stutterheim, Casper Rokx (Rotterdam, Netherlands)

Scientific Posters

Public health strategies and options (continued)

P311	**Implementation of HIV screening and direct connection to care in an emergency department in very large US hospital** Jeffrey Kuhlman (Orlando, FL, USA)
P312	**Smoking and HIV in the UK: prevalence, patterns and associated factors in the Positive Voices 2022 cross-sectional study** Tamsin McKinnon, Fiona Lampe, Fumiyo Nakagawa, Janey Sewell, Marc Lipman, James Brown, Bernard Kelly, Shalini Andrews, Alex Sparrowhawk, Carole Kelly, Meaghan Kall, Valerie Delpech Andrew Phillips, Colette Smith, Alison Rodger, on behalf of PV2022 Study Group (London, UK)
P313	**From recommendation to routine: what it takes to integrate HIV testing into European hospital care** Klaske Vliegenthart-Jongbloed, Divya Purwaha, Winston van Druten, Casper Rokx, on behalf of #aware.hiv Europe Study Group (Rotterdam, Netherlands)
P314	**Projected public health impact of removing financial barriers to PrEP in high-incidence populations** Turgay Ayer, JeanPierre Coaquira Castro, Emir Gursel, Alice Hsiao, Woodie Zachry, Patrick Sullivan (Foster City, CA, USA)
P315	**Age and syndemic disparities in clinician-initiated HIV screening in the emergency department and projected impact of an automated opt-out bundle** Omvikneswer Muralitharan (Foster City, CA, USA)
P316	**Phylogenetic investigation of HIV-1 integrase L74I in Greece and Poland: evidence for subtype-dependent onward transmission** Evangelia Georgia Kostaki, Karol Serwin, Eleni Papachristou, Kaja Mielczak, Alexandros Vassilakis, Chrysoula Rokka, Panagiotis Iliopoulos, Pagona Lagiou, Gkikas Magiorkinis, Miłosz Parczewski, Dimitrios Paraskevis (Athens, Greece)
P317	**Healthcare worker HIV stigma and willingness to provide care for key populations in Taiwan: findings from integrated WHO and HPASS measures** Su-Han Hsu, Hsin-Hao Lai, Shan-Lin Liu, Chien Chun Wang, Tsen-Fang Yen, Chih Chieh Tsai (Taipei, Taiwan)
P318	**Strategies for recruiting and retaining pregnant and breastfeeding women living with HIV in pharmacokinetic studies in Uganda** Ritah Nakijoba, Aida N Kawuma, Simon Peter Asiimwe, Christine Turyahabwe, Jacqueline Kyeyune, Johnson Magoola, Francis W Ojara, Catriona Waitt (Kampala, Uganda)
P319	**TURHIV-DR: a nationwide multicentre study of transmitted HIV-1 drug resistance among treatment-naïve people living with HIV in Türkiye** Ilkay Akbulut, Tülin Demir, Zeynep Sedef Varol, Taliha Karakök, Ayşe Deniz Gökengin, Sabri Atalay, Emel Eroğul, Esra Duru Oz, Arzu Varlı, Ilker Odemis, Ekrem Sağtaş, Mehmet Balcı, Yesim Tasova, Nefise Oztoprak Cuvalci, Meliha Cagla Sonmezer, Adalet Altunsoy, Tuna Demirdal, Ilkay Karaoglan, Elif Doyuk Kartal, Cigdem Ataman Hatipoglu, Dilara Inan, Sua Sumer, Ozgur Gunal, Aydın Deveci, Bircan Kayaaslan, Deniz Ozer, Gonul Cicek Senturk, Aliye Bastug, Mehmet Cabalak, Aysin Kılınç Toker, Selcuk Kaya, Nevin Ince, Haluk Erdogan, Zehra Karacaer, Husnu Pullukcu, Mehmet Serhat Birengel, Yesim Yildiz, Veysel Akca, Tuba Damar Cakirca, Meltem Arzu Yetkin, Funda Memisoglu, Ayse Albayrak, Gamze Kalin Unuvar, Gulden Ersoz, Habibe Tulin Elmaslar Mert, Fehmi Tabak, Selma Ates, Ahmet Cağkan Inkaya, on behalf of TURHIV-DR Study Group (Izmir, Türkiye)
P320	**Real-time automation and detection of HIV-1 transmission clusters: pilot validation of the SIEGA-MicrobeTrace system** Paloma Muñoz-Baez, Andrea Aguado, Marta Illescas-Lopez, Antonio Ramirez-Hurtado, Iberto Vazquez-Blanquiño, Gema Roldan, Ana Alberola, Maria Lara, Lucia Perez, Javier Perez-Florido, Adolfo De Salazar, Carlos Sanchez, Casimiro Soriguer, Federico Garcia (Granada, Spain)

Scientific Posters

Public health strategies and options (continued)

P321	**Natural prevalence of HIV-1 capsid inhibitor resistance-associated mutations in southern Taiwan: a retrospective study (2022–2025)** Hung-Chin Tsai, I-Tzu Chen, Ya-Wei Weng, Yu-Ting Tseng, Jui-Kuang Chen, Kuan-Sheng Wu (Kaohsiung, Taiwan)
P322	**The RIDING cohort: access to care and one-year outcomes among migrant people with HIV in Madrid** Juan Carlos Donaire, Noemi Cabello, Samuel Manzano, Maria Jesus Vivancos, Rafael Mican, Otilia Bisbal, Violeta Samperiz, Aws Al-Hayani, Sara de la Fuente, Laura Sindín-Martín, Cristina Hernandez, Oriol Martin-Segarra, Alejandra Gimeno, Juan Quintero, Fernando Duran, Nieves Sanz, Pablo Ryan, Belen Milla-Olaya, Maria del Mar Arcos, Belen Sanchez-Lopez, Lucio Garcia-Fraile, Alfonso Cabello, Alberto Diaz de Santiago, Irene Cabello-Rojano, Maria Novella, Marta de Miguel, Olaya Huergo, Claudia Dorta, Miriam Estebanez, Jose Maria Bellon, Teresa Aldamiz-Echevarria, on behalf of RIDING Study Group (Madrid, Spain)
P323	**Abstract withdrawn**
P324	**Diagnostic pathways and missed opportunities for HIV testing among heterosexual individuals newly diagnosed with HIV** Claudia Nevado Pavón, Xabier Kortajarena Urkola, Maialen Lekuona Sanz, Miguel Ángel Goegana Sánchez, Harkaitz Azkune Galparsoro, Xabier Camino Ortiz de Barrón, Ignacio Álvarez Rodríguez, Maialen Ibarguren Pinilla, Francisco de Asís Carmona de la Torre, Mª Jesús Bustinduy Odriozola, Ana Bayona Carlos, Leire Gil Alonso, Leire Balerdi Sarasola ander Goyache Moreno, Jose Antonio Iribarren Loyarte (San Sebastian, Spain)
P325	**Recombinant zoster vaccination uptake and determinants in people with HIV in the Swiss HIV Cohort Study** Emma Tinguely, Bernard Surial, Alain Amstutz, Marcel Stöckle, Luigia Elzi, Patrick Schmid, Oksana Fiammingo, Alexandra Calmy, Matthias Cavassini, David Haerry, Irene A Abela, Marius Zeeb, on behalf of Swiss HIV Cohort Study (Bern, Switzerland)
P326	**The impact of perceptions: exploring patient opt-out despite pre-test counselling and stigma reduction efforts in a standardised emergency department STI screening programme** Makayla Sinness, Andrew Salter, Jessica Chavez (Westminster, CO, USA)
P327	**Social vulnerability is associated with persistent detectable viraemia in a Brazilian real-world HIV cohort** Pietra Stanicki, Karen Ingrid Tasca, Alexandre Naime Barbosa (SP, Brazil)
P328	**Abstract withdrawn**
P329	**Abstract withdrawn**
P330	**Abstract withdrawn**
P331	**Tale of three pandemics – disparities in HIV risk profile, access to care and treatment success, comparing a rural-mining community, a semi-urban area and an urban area in Cameroon** Patrick Herve Mfondoum (Yaounde, Cameroon)
P332	**Prevalence of BBV and syphilis in those presenting to Cardiff and Vale Health Inclusion Service (CAVHIS)** Leah Sell, Rhys Oakley, Ayla Cosh, Bazga Ali (Cardiff, UK)
P333	**Integrating a gender perspective into HIV care: a qualitative study in a specialized hospital in Buenos Aires, Argentina** Romina Mauas, María Fernanda Rombini, Isabel Cassetti, Mario Martin Pecheny (Buenos Aires, Argentina)

Scientific Posters

Public health strategies and options (continued)

P334	**Factors associated with HIV-1 infection recency among newly HIV diagnosed individuals in the era of "Treat All" in Botswana** Goitseone Lemogang, Natasha Moraka-Mankge, Charity Ralegoreng, Richard Makwakwa, Marea N Pema, Patrick T Mokgethi, Ontlametse T Choga, Dorcas Maruapula, Salang T Moutswi, Laone Rabatoko, Queen Leteemane, Vanessa Strachan, Phenyo Sabone, Terence Mohammed, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)
P335	**Developing an AI-powered chatbot integrated into an anonymous STI partner notification app: insights from a survey among PrEP users** Felix Straga, Maria del Carmen Navarro, Marta Navarro, Sonia Calzado (Barcelona, Spain)
P336	**A twelve-fold expansion of subtype F and the rise of E138A: molecular transformation of the HIV-1 epidemic in southern Türkiye, 2016–2024** Aslıhan Candevir, Tülin Demir, Ferit Kuşcu, Süheyla Kömür, Ayşe Seza İnal, Damla Ertürk, Özgür Ogün Sayın, `Ömer Faruk Yardımcı, Behice Kurtaran, Yeşim Taşova (Adana, Türkiye)
P337	**Burden of socio-structural vulnerability and self-perceived health in people living with HIV receiving clinical care in Mexico** Hector Rivera, Jessica Mejia, Yanink Caro, Fernanda Ramos, Ever Corral, Alvaro Lopez, Paola Alarcon, Geovanna Coello, Brenda Crabtree (Mexico City, Mexico)
P338	**Implementation of an infectious diseases clinic for sexual diversity within the public health system (PHS) of Buenos Aires, Argentina** Iael Altclas, Maria Teresa Rodriguez Brieschke, Pablo Scapellato (Buenos Aires, Argentina)
P339	**Client-centred digital approaches for ensuring continuity of HIV care and support programmes in Ukraine** Nataliia Zapolska, Diana Shevchenko, Larysa Hetman, Liudmyla Legkostup (Kyiv, Ukraine)
P340	**HIV infection, confirmed recent infection and sentinel events among newly diagnosed HIV cases in Enugu State: insights from case-based surveillance** Anuli Oyeka, Oluwaseun Garuba, Yakubu Yusuf, Patience Muogbo, Bidi Tordue, Chukwudi Okwor, Fabian Bassey, Ifeoma Tony-Monye, Victor Enejoh, Mabwe Kuba, Eugene Onu, Lawrencia Agur, Young Oluokun, Amana Effiong, John Oko, Olumide Okunoye, Olufemi Oke, Flora Nwagagbo, Jerry Gwamna (Abuja, Nigeria)
P341	**HIV-1 subtypes dynamic and transmission drug resistance among patient followed in Tel Aviv area between years 2001–2025** Dan Turner, Rotem Marom, Katia Levytskyi, Steven Rapaport, Eugene Katchman, Svetlana Ahsanov, Natasha Matus, Shirley Girshengorn, Luba Tau (Tel Aviv, Israel)

Cost and cost-effectiveness

P342	**Return on investment of eliminating insurance barriers to PrEP in high-incidence populations** Emir Gursel, JeanPierre Coaquira Castro, Turgay Ayer, Alice Hsiao, Woodie Zachry, Mert Edali, Patrick Sullivan (Foster City, CA, USA)
P343	**Projected health benefits and economic value of combined opt-out testing for HIV/HBV/HCV in urban emergency departments in Germany, Greece and Poland** Magdalena Rosińska, Robert Flisiak, Andrzej Fal, Justyna Kowalska, Harmut Stocker, Mina Psichogiou, Charalampos Gogos, George Papatheodoridis, Nikolaos Mangafas, Laurel Bates, Xinlu Pan, Andrea Polokaova, Erik Robinson, Hairuo He, James Jarrett, Murad Ruf, Jürgen Rockstroh (London, UK)

Scientific Posters

Cost and cost-effectiveness (continued)

P344	**Economic impact of extended monitoring intervals in people with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide: an Italian real-world analysis (EXTEND-BIC study)** Diego Ripamonti, Roberta Gagliardini, Valentina Perrone, Stefania Mazzoni, Luca Degli Esposti, Laura Albini, Gabriele Forcina, Giovanni Di Perri (Bergamo, Italy)
P345	**An annual HIV review pathway: delivering safe, sustainable and high-value care** Lily Edwards, Rachel Kirby, Callum Neill, Justine Mellor, Vincent Lee (Manchester, UK)
P346	**Expanding HIV pre-exposure prophylaxis could reduce new HIV infections by 69% and generate long-term cost savings in Italy** Chiara Bini, Valentina Mazzotta, Silvia Nozza, Martina Paoletti, Virginia Scansetti, Paolo Sciattella (Rome, Italy)
P347	**Closing the gap to zero HIV transmission: modelling the impact of long-acting injectables (LAI) in the UK** Melanie Schroeder, Johan Klint, Jonathan Tosh, Rob Blissett, Sarah-Jane Anderson, Gavin Jones, Jeremy Fraysse, Julie Priest (London, UK)
P348	**Historical pricing dynamics of generic antiretroviral agents: implications for the future introduction of TLD in high-income countries** Piter Oosterhof, Kees Brinkman, David Burger (Amsterdam, Netherlands)
P349	**Translating evidence into practice: a comparative analysis of international HIV treatment guidelines on medication cost-driven ART optimization** Piter Oosterhof, Kees Brinkman, David Burger (Amsterdam, Netherlands)
P350	**Abstract withdrawn**
P351	**Cost-effectiveness of a low-intensity primary care educational intervention to reduce late HIV diagnosis in Madrid, Spain** Alejandro García-Ruiz de Morales, Javier Martinez Sanz, Rosas Marta, Maria Jesus Vivancos, Beatriz Romero-Hernández, Beatriz Mateos, Ana Moreno Zamora, Santiago Moreno Guillén, Maria Jesus Perez Elias, on behalf of Atenea Study Group (Madrid, Spain)
P352	**Abstract withdrawn**

Models of care: evaluation of ARV delivery and coverage

P353	**European healthcare providers' PrEP practices and barriers to equitable access for migrant populations: insights from an EACS-network survey** Haoyi Wang, Anne Flaherty-Gupta, Hala Majdoub, Juan Soto, Gonçalo Lobo, Joëlle Verluyten, Kai Jonas, Hanne Zimmermann, Denis Onyango (Maastricht, Netherlands)
P354	**Trajectories of sustained virological suppression over time are not determined by socio-economic factors in the Netherlands** Kyra Mendes de Leon, Ferdinand Wit, Marc Van der Valk, Vita Jongen (Amsterdam, Netherlands)
P355	**Towards annual monitoring in HIV care: a rapid review of outcomes and implementation considerations** Breda Patterson, Nicola Galbraith, Laura Waters, Liz Walder, Phillipa Pristerà (London, UK)
P356	**Clinician reported reasons for switching antiretroviral medications in the publicly funded HIV drug treatment programme in British Columbia, Canada: a real-world 16-year retrospective analysis (2009-2024)** Rosie B Murphy, Sandra Chang, Cassidy Tam, Raquel M Espinoza, Jason Trigg, Paul Sereda, Wendy Zhang, Julio SG Montaner, K Junine Toy (Vancouver, Canada)

Scientific Posters

Models of care: evaluation of ARV delivery and coverage (continued)

P357	**Sex work identifies structural vulnerability and lower retention among migrants living with HIV in Barcelona, 2010–2023** Elizabeth Zamora-Clemente, Lorena De La Mora, Leire Berrocal, Berta Torres, Ana González-Cordón, María Martínez-Rebollar, Montserrat Laguno, Juan Ambrosioni, Iván Chivite, Elisa de Lazzari, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Raquel Aguiló, Esteban Martínez, José M Miró, José Luis Blanco, Josep Mallolas, Alexy Inciarte (Barcelona, Spain)
P358	**Venezuelan migrants living with HIV in Barcelona, Spain: addressing knowledge gap in Europe, an historical cohort** Alexy Inciarte, Elizabeth Zamora-Clemente, Leire Berrocal, Ana González-Cordón, Lorena De La Mora, María Martínez-Rebollar, Montserrat Laguno, Juan Ambrosioni, Iván Chivite, Elisa de Lazzari, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Esteban Martínez, José M Miró, José Luis Blanco, Berta Torres, Josep Mallolas (Barcelona, Spain)
P359	**Abstract withdrawn**
P360	**BRIDGE study: evaluating prior antiretroviral therapy in foreign-born people living with HIV entering care in Spain** Verónica Gil-Girona, Francisco Jover-Diaz, Jorge Peris-Garcia, Elisabet Delgado-Sánchez, Andrea Riaño-Pérez, Mari Ángeles Bernabeu-Martínez (Alicante, Spain)
P361	**Abstract withdrawn**
P362	**Using a large language model to classify reasons for multi-tablet regimen use in people living with HIV: a pilot study within the Swiss HIV Cohort Study** Lena Bartl, Marius Zeeb, Cedric Dolle, Krystyna Vulchanova, Johannes Nemeth (Zürich, Switzerland)
P363	**Effectiveness and implementation outcomes of a co-designed, person-centred care model for people living with HIV in Delta State, Nigeria: a hybrid stepped-wedge cluster-randomised trial** Bonaventure Ukoaka, Awajinor Ismael, Nerrisa Okwuokei, Morayo Happy Akinyomi, Oghenekparobor Elijah, Chinazom Ifedigbo, Gerald Oraegbu, Etieno Mbaba, Saviour Wilson, Henry Udenenwu, Grace Jimbo, Okezie Onyedinachi andy Eyo (Delta, Nigeria)
P364	**Patterns of HIV care transfer amongst migrant populations in two HIV clinics in Hertfordshire: identifying trends in antiretroviral therapy, treatment interruptions and virological suppression** Sorina Bolache, Marta Boffito, Rasha Dabis, Sarah Edwards, Nadia Naous (London, UK)
P365	**An evaluation of the HIV in-reach service at a multi-hospital urban centre: a new model for HIV inpatient care** Oliver Hug, Tamara Elliott, Lauren Nicholls, Lucy Garvey, Nicola Mackie, Linda Greene, Demiana Sidhom, Rory Grier-Gavin, Borja Mora-Peris (London, UK)
P366	**Capacity modelling in HIV care: workforce implications of a nurse-led long-acting injectable ART service** Amy Walsh, Aoife G Cotter, Christine Kelly, Padraig McGettrick, Eavan Muldoon, James Woo, Mairead O'Connor, Tara McGinty (Dublin, Ireland)
P367	**PERDÍ-VIH study: model of care evaluation and risk factors for loss to follow-up in people living with HIV** Andrés Fernández-Montealegre, Francisco Jover-Díaz, Maria Ángeles Bernabeu-Martínez, Elisabet Delgado-Sánchez, Andrea Riaño-Pérez, Jorge Peris-Garcia (Alicante, Spain)
P368	**Clinical dataset findings from the evaluation of the EXPAND NEL North East London-wide digital oral PrEP pilot** Laura Leigh Vetters, Melanie Smuk, Ollie Lloyd-Houldey, Nishat Halim, Sara Paparini, Vanessa Apea, Chloe Orkin (London, UK)

Scientific Posters

Models of care: evaluation of ARV delivery and coverage (continued)

P369	**Survey findings from the evaluation of the EXPAND NEL North East London-wide digital oral PrEP pilot** Laura Leigh Vetters, Melanie Smuk, Ollie Lloyd-Houldey, Nishat Halim, Sara Paparini, Vanessa Apea, Chloe Orkin (London, UK)
P370	**"U=U for all": the personal and public health Impact of long-acting injectable antiretrovirals in a systematically marginalised population of people living with HIV at the Kirketon Road Centre** Bruce Taylor, Vendula Belackova, Ian Anderson, Matilda Eyre, Lucy Fromel, Sam King, Eugene Priscott, Phillip Read, Yen Li (Sydney, Australia)

Co-morbidities and complications of disease and/or treatment: Ageing and frailty

P371	**Immune-inflammatory profile with high inflammation, innate immune activation and immunosenescence is associated with higher mortality in people with HIV** Moises Alberto Suarez-Zdunek, Ayleen Mufudza, Andreas Dehlbæk Knudsen, Sisse Rye Ostrowski, Marius Trøseid, Thor Ueland, Thomas Benfield, Patrick WG Mallon, Susanne Dam Nielsen (Copenhagen, Denmark)
P372	**Antiretroviral therapy use in ageing people with HIV: RESPOND cohort study** Olof Elvstam, Jaime Vera, Ferdinand Wit, Marc van der Valk, Ole Kirk, Lene Ryom, on behalf of RESPOND Study Group (Malmö, Sweden)
P373	**Beyond viral suppression: loneliness and financial hardship independently predict high unmet-needs burden in older people living with HIV — a national community-based survey in Italy** Giovanni Guaraldi, Aurelio Castro, Jovana Milic, Michela Belli, Giusi Giupponi, Patrizia Perrone, Sabrina Penon, Salvo Cecere, Chiara Solico, Stefano Patrucco, Aleksandra Moznic, Luca Butini, Paolo Meli, Leonardo Del Negro, Maria Stagnitta, Daniela Masci, Hermine Gbedo, Filippo von Shlosser, Mario Cascio, Nicoletta Policek, Alessandra Bianchi, Colette Smith (Modena, Italy)
P374	**Age is independently associated with incident low-level viraemia during suppressive antiretroviral therapy: data from the ICONA cohort** Anna Maria Geretti, Roberta Gagliardini, Davide Checchi, Camilla Muccini, Alessandra Vergori, Valentina Mazzotta, Giuseppe De Socio, Alessandro Tavelli, Giulia Marchetti, Loredana Sarmati, Antonella D'Arminio Monforte, Cristina Mussini, Andrea Antinori, Alessandro Cozzi-Lepri, on behalf of ICONA Cohort Study Group (London, UK)
P375	**The impact of semaglutide on weight loss and inflammation in people with HIV: an observational prospective study in Greek population** Vasileios Petrakis, Periklis Panagopoulos, Petros Rafailidis, Maria Panopoulou, Dimitrios Papazoglou (Alexandroupolis, Greece)
P376	**Association of anti-Müllerian hormone with oxidative stress, microbial translocation and monocyte activation following cART initiation in women with HIV** Valeria Bono, Valentina Sala, Mariacristina Poliseno, Alessandro Tavelli, Hanieh Sadeghi, Eugenia Quiros-Roldan, Matteo Augello, Giuseppe Vittorio De Socio, Carmen Santoro, Claudia Maestripieri, Cristina Mussini, Miriam Lichtner, Camilla Tincati, Annalisa Saracino, Giulia Marchetti, on behalf of ICONA Cohort Study Group (Milan, Italy)
P377	**Polypharmacy, anticholinergic burden (ACB) and potential drug-drug interactions (PDDIs) in older people living with HIV (PLWH) who attended a HIV outpatient clinic, including a specialist joint HIV and geriatric medicine service (Platinum Clinic)** Arlene Heekin, Miriam Moriarty, Gail Melanophy, David Robinson, Emma Devitt (Dublin, Ireland)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: Ageing and frailty (continued)

P378	**Sarcopenia, frailty and biological age in people living with HIV** Jose L Casado, Laura Luna, Isabel Izuzquiza, Ana Moreno, Cristina Fernandez-Chica, Alejandro Vallejo (Madrid, Spain)
P379	**Abstract withdrawn**
P380	**Never too old to recover: a longitudinal analysis of people with HIV aged ≥ 75 years in the ICONA cohort** Camilla Muccini, Andrea De Vito, Alessandro Tavelli, Andrea Santoro, Giovanni Festa, Eugenia Quiros-Roldan, Cecilia Costa, Andrea Calcagno, Giulia Marchetti, Antonella Cingolani, Enrico Girardi, Antonella D'Arminio Monforte, Giovanni Guaraldi, Giordano Madeddu, on behalf of ICONA Cohort Study Group (Milan, Italy)
P381	**Outcomes and comorbidity burden among people diagnosed with HIV at age ≥ 60 years: the German ClinSurv cohort** Smaranda Gliga, Uwe Koppe, Christian Kollan, Andrea Sailer, Guido Schäfer, Matthias Müller, Peter Buggisch, Dirk Schürmann, Stefan Esser, Alexander Killer, Tom Luedde, Barbara Gusenheimer-Bartmeyer, Björn-Erik Ole Jensen, on behalf of ClinSurv Study Group (Dusseldorf, Germany)
P382	**Elderly people living with HIV on successful modern treatment have increased levels of immunosenescence, with men who have sex with men displaying the highest level** Matteo Vassallo, Jacques Durant, Sami Addou, Michel Ticchioni, Roxane Fabre, David Chirio, Sara Ferrando, Alissa Naqvi, Eric Cua, Leslie Ameil, Maeva Godemert, Edouard Tuaillon, Amandine Pisoni, Anaelle Bisch, Jacqueline Capeau, Christian Pradier, Michel Carles (Cannes, France)
P383	**Expectations regarding ageing as a potential entry point to identify depressive symptoms in long-term HIV care: a Japanese multi-centre study with HIV-negative controls** Hideta Nakamura, Kazutaka Yamaniha, Nanae Ikemiyagi, Shuhei Ideguchi, Shin Yamashiro, Hitoshi Tamaki, Masashi Narita, Michinori Shirano, Sei Samukawa, Tomoyuki Endo, Junji Imamura, Mayumi Imahashi, Rumi Minami, Kazuko Yamamoto (Ginowan, Japan)
P384	**Aging with HIV: longitudinal changes in social support among people aged ≥ 50 in the ELEA-Brasil cohort** Camilla Ferreira Santos, Roberta Schiavon Nogueira, Lucas Rocker Ramos, Giovanna Haimowski, Marilia Bordignon Antonio, Leticia Sanchez Labadia Hypolito, Márlon Juliano Romero Alibert, Beatriz Grinsztejn, Sandra Wagner Cardoso, Thiago S Torres, Carlos Brites, Estela Luz, Marcio H Pimenta, Paridhi Ranadive, Jessica L Castilho, on behalf of ELEA-Brasil Cohort (São Paulo, Brazil)
P385	**HIV induced microglial senescence: a potential driver of neuroinflammation and HAND** Pratiksha Pansambal, Vitthal Barvkar, Swarali Kurle (Maharashtra, India)
P386	**Aging with HIV: a cross-sectional analysis of comorbidities among older people living with HIV in Saudi Arabia** Roaa Alosaimi, Batool Ali, Alaa Malki, Ibrahim Alshehri (Jeddah, Saudi Arabia)
P387	**Polypharmacy, pill burden, drug-drug interactions, quality of medication history documentation and rates of HIV pharmacy review in the person ≥ 75 years living with HIV: a retrospective audit at a specialist HIV service the Albion Centre, Sexual Health and Blood Borne Virus, South Eastern Sydney Local Health District, Sydney, Australia** Yen Li Lim, Natasha McLellan, Melissa Kelly, Arthur Wong, Bruce Hamish Bowden (Sydney, Australia)
P388	**Closing clinical gaps across specialties: online CME on HIV-driven chronic inflammation** Graeme Moyle, Santiago Moreno, Shanthi Voorn, Gill Adair, Alessia Piazza, Ewen Legg (London, UK)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: CV/metabolic including weight gain

P389	**The impact of viraemia on diabetes in the modern INSTI era: a time-updated analysis** Giovanni Festa, Dario Diana, Nicolò Capra, Riccardo Lolatto, Silvia Nozza, Angelo Roberto Raccagni, Hamid Hasson, Golnaz Torkjazi, Flavia Passini, Antonella Castagna, Vincenzo Spagnuolo, Tommaso Clemente (Milan, Italy)
P391	**Barriers and facilitators to statin prescribing in hospital-based HIV care: insights from a Dutch clinician survey** Rosa Elias, Kim Romijnders, Casper Rokx, Judith Branger, Aafke Cents-Bosma, Fanny Lauw, Annelies Verbon, Berend van Welzen (Utrecht, Netherlands)
P392	**No impact of metformin on body fat compartments, including visceral fat, as measured by whole body magnetic resonance imaging in the MAVMET trial** James Burns, Augustus Rottenburg, Abulrahman Mohamed, Stuart Taylor, Naomi Sakai, Chloe Dennis, Yolanda Collaco-Moraes, Frank Post, Julie Fox, Margaret Johnson, Lucy Garvey, Chloe Orkin, David Dunn, Sarah Pett, Manil Chouhan, on behalf of MAVMET Study Group (London, UK)
P393	**Cardiovascular risk assessment by imaging in people with HIV: added value compared with clinical risk scores and impact on preventive management** Martin Chaix, Remy Duong, Dominique Batisse, Marina Karmochkine, Juliette Pavie, Anne Rachline, Laurence Slama, Jean Paul Viard, Romain Palich, Clémentine de La Porte des Vaux (Paris, France)
P394	**Metabolic outcomes after switch to long-acting CAB+RPV versus DOR/3TC/TDF in virologically suppressed people with HIV: a real-world cohort study** Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, Andrea Giacomelli, Sasha Trevisan, Andrea Carbone, Andrea De Vito, Maria Vittoria Cossu, Massimiliano Fabbiani, Emilio Altavilla, Francesco Bassani, Filippo Lagi, Alberto Borghetti, Chiara Papalini, Giordano Madeddu, Spinello Antinori, Andrea Gori, Cristina Mussini, Simona Di Giambenedetto (L'Aquila, Italy)
P395	**Incident MASLD during the first year after HIV diagnosis: longitudinal changes in liver metabolic health from the prospective MASHIV-TR cohort** Ayşe Özlem Mete, Çiğdem Mermutluoğlu, Yeşim Taşova, İlkay Karaoğlan, Hüsnü Pullukçu, Meliha Çağla Sönmezer, Dilara İnan, Funda Şimşek, Sıla Akhan, Tuba Damar Çakırca, Nursel Çalık Başaran, Aslıhan Candevir, Yeliz Çiçek, Damla Ertürk, Ahmet Çağkan İnkaya, İsmail Yıldız, Behice Kurtaran, Müge Toygar Deniz, Yaşar Bayındır, Mustafa Kemal Çelen (Diyarbakir, Türkiye)
P396	**Reframing obesity in HIV care: agreement between BMI and the Lancet Commission definition** Jovana Milic, Enrico Roma, Licia Gozzi, Marianna Menozzi, Lorenzo Benassi, Severino Ambrosio, Cristina Mussini, Giovanni Guaraldi (Modena, Italy)
P397	**Abstract withdrawn**
P398	**Implementation of a multi-component mHealth programme as differentiated service delivery model for people with HIV and cardiometabolic comorbidities** Grace CY Lui, Rebecca KK Yuen, Heather WK To, Bonnie CK Wong, Tracy HY Ho, Fion WL Luk, Shui-Shan Lee, Candy NS Wong (The Chinese University of Hong Kong, Hong Kong)
P399	**Sex-specific patterns of cardiovascular-kidney-metabolic syndrome progression in people with HIV** Jovana Milic, Laura Biondi, Lorenzo Salmoni, Alessandro Pecchi, Matteo Menozzi, Marianna Menozzi, Sonia Generoso, Gian Luca Cuomo, Giuseppe Mancini, Cristina Mussini, Giovanni Guaraldi (Naples, Italy)
P400	**Longitudinal changes and risk factors of steatotic liver disease in people with HIV in Switzerland** Eloïse Magnenat, Nadia Meyer, Annalisa Berzigotti, Isabella C Schoepf, David Haerry, Huldrych F Günthard, Philip E Tarr, Andri Rauch, Bernard Surial, Gilles Wandeler, Anders Boyd, Carlotta Mondoka, on behalf of Swiss HIV Cohort Study (Bern, Switzerland)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: CV/metabolic including weight gain (continued)

P401	**Evaluation of weight at week 48 in a phase 3 study in adults initiating treatment for HIV-1 with doravirine/islatravir (100 mg/0.25 mg) versus bictegravir/emtricitabine/tenofovir alafenamide** Jurgen Rockstroh, Gary Sinclair, Brenda Crabtree Ramírez, Sheetal Kassim, Jean-Michel Molina, Anchalee Avihingsanon, Dorothy McCoy, Yayun Xu, Stephanie Klopfer, Michelle Fox, Mary Pisculli (Bonn, Germany)
P402	**Glucagon-like peptide-1 receptor agonists and musculoskeletal outcomes: a longitudinal study in people living with HIV** Marianna Menozzi, Jovana Milic, Alessandro Pecchi, Gianluca Cuomo, Giuseppe Mancini, Uberto Calvi, Filippo Calandra, Cristina Mussini, Giovanni Guaraldi (Modena, Italy)
P403	**Characterisation of metabolic liver disease in people living with HIV using liver elastography: a prevalence study** Claudia Maya Salazar, Bianca P Aguilar Rodea, Jezer Lezama Mora, Luis Eduardo Cázerez Villareal, Eva Juárez Hernández, Iván López Méndez (Mexico City, Mexico)
P404	**Incidence of metabolic syndrome in people with HIV who start dolutegravir based-regimen compared with bictegravir based-regimen after 96 weeks (MICTLAN study)** Mara Rodriguez Evaristo, Jose Antonio Mata Marin, Ana Luz Cano Diaz, Emily Pecero Garcia, Gloria Elizabeth Salinas Velázquez, Alberto Chaparro Sanchez, Ericka Pompa Mera, Betzahida Meneses Cisneros, Jesús Enrique Gaytan Martínez (Mexico City, Mexico)
P405	**Long-term progression of hepatic steatosis and fibrosis in people with HIV: a 5-year longitudinal cohort study** Wei Xu, Wei Song, Li Liu, Renfang Zhang, Jun Chen, Yinzhong Shen (Shanghai, China)
P406	**From primary to secondary cardiovascular prevention among people living with multidrug-resistant HIV: missed opportunities in the statin cascade of care in the PRESTIGIO registry** Tommaso Clemente, Dario Diana, Riccardo Lolatto, Giovanni Cenderello, Giulia Carla Marchetti, Simona Di Giambenedetto, Golnaz Torkjazi, Daniela Messeri, Giordano Madeddu, Vincenzo Malagnino, Giovanni Festa, Stefano Rusconi, Laura Comi, Vincenzo Spagnuolo, on behalf of PRESTIGIO Study Group (Milan, Italy)
P407	**Is menopause really a cardiovascular turning point in women with HIV?** Laura Eleonora Biondi, Filippo Calandra Buonaura, Marianna Menozzi, Cristina Mussini, Giovanni Guaraldi, Jovana Milic (Modena, Italy)
P408	**Lower incidence of TyG-defined insulin resistance after boosted protease inhibitor-to-dolutegravir switch in people with HIV at high cardiovascular risk: NEAT-022** Abiu Sempere, Lambert Assoumou, Ana González-Cordón, Laura Waters, Stefano Rusconi, Pere Domingo, Mark Gompels, Stephane De Wit, François Raffi, Christoph Stephan, Mar Masía, Jürgen Rockstroh, Christine Katlama, Georg M Behrens, Graeme Moyle, Margaret Johnson, Julie Fox, Hans-Jürgen Stellbrink, Giovanni Guaraldi, Eric Florence, Stefan Esser, José M Gatell, Anton Pozniak, Esteban Martínez, on behalf of NEAT-022 Study Group (Barcelona, Spain)
P409	**Statin cascade of care in people living with HIV reveals missed opportunities for cardiovascular prevention: a retrospective cohort study** Christos Arkadianos, Konstantinos Protopapas, Charalampos D Moschopoulos, Christos Filis, Kimon Koussoulakos-Vassilounis, Elias Ernst Lykos, Anna Maria Loukaidou, Dimitra Kavatha, Antonios Papadopoulos (Athens, Greece)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: CV/metabolic including weight gain (continued)

P410	**Improved statin prescribing in people living with HIV but persistent gaps in highest-risk patients: a multi-site service evaluation** Bethany Harrison, Courtney Murray, Paul Hine (Liverpool, UK)
P411	**Abstract withdrawn**
P412	**Atherogenic index of plasma (AIP) as a stable pre-event marker of major adverse cardiovascular events in people with HIV: a time-anchored matched case-control study from the ICONA cohort** Nicola Squillace, Simone Lanini, Alessandro Tavelli, Marco Cotrufo, Roberta Gagliardini, Matteo Augello, Carlo Torti, Jacopo Vecchiet, Anna Beltrami, Antonella Castagna, Antonio Di Biagio, Giordano Madeddu, Alessandra Bandera, Giovanni Guaraldi, Sergio Lo Caputo, Andrea Antinori, on behalf of ICONA Study Group (Monza, Italy)
P413	**Switching from TAF-based regimens to long-acting therapy versus FTC/TAF/BIC: differential effects on weight and lipid profile in people with HIV** Nicola Squillace, Elena Delfina Ricci, Lucia Taramasso, Teresa Bini, Barbara Menzaghi, Giancarlo Orofino, Giordano Madeddu, Sergio Ferrara, Giuseppe Vittorio De Socio, Giovanni Cenderello, Emanuele Pontali, Stefania Piconi, Giovanni Francesco Pellicano', Antonio Di Biagio, Paolo Bonfanti, on behalf of CISAI/SCOLTA Study Group (Monza, Italy)
P414	**Sex disparities in cardiovascular risk factor burden and preventive care among people with HIV across three antiretroviral therapy eras** Jovana Milić, Laura Eleonora Biondi, Michela Belli, Elisabetta Delmonte, Irene Avanzini, Cristina Mussini, Giovanni Guaraldi (Modena, Italy)
P415	**Applying the 2025 AHA/ACC definition triples the incidence of hypertension in people with HIV compared with EACS** Jovana Milić, Alessandra Carobbio, Anna Katrine Haslund Roed, Eugenio Carriero, Lorenzo Salmoni, Filippo Buffagni, Cristina Mussini, Susanne Dam Nielsen, Giovanni Guaraldi, Esteban Martinez (Modena, Italy)
P416	**Metabolic impact of switching to doravirine-based regimens in treatment-experienced people living with HIV: 48-week results from the DOLART study in Argentina** Diego Cecchini, Edgardo Bottaro, Gastón Copertari, Martín Brizuela, Carla Serrano, María Magdalena Puchulu, Juan Manuel Nuñez, Juan Gonzalo Tomás, Macarena Roel, Isabel Cassetti (Buenos Aires, Argentina)
P417	**Incretin-based therapies in people with HIV: weight, glycaemic and virological outcomes in a real-world cohort** Ling-Ya Chen, Yi-Ting Chen, Hsin-Yun Sun, Hsi-Yen Chang, Yu-Zhen Luo, Pei-Ying Wu, Chien-Ching Hung (Taipei, Taiwan)
P418	**PNPLA3 rs738409 polymorphism is associated with non-alcoholic fatty liver disease in treatment-naïve HIV-infected individuals, predominantly in lean patients** Yanyan Li, Hongxia Wei, Qin Wang, Chen Chen, Rentian Cai, Lianfeng Lu, Shuo Yang, Jiale Chi, Chunmiao Zou, Ping Luo (Nanjing, China)
P419	**Moderate/severe steatotic liver disease (SLD) and at-risk MASH in people with and without HIV** Alejandro Arenas-Pinto, Maeve Barlow, Andrew Copas, Sarah Pett, Agnieszka Kemper, Florence Bascombe, Kat Johnson, Sadiyah Mukhtar, Indrajit Ghosh, Stuart Flanagan, Richard Gilson (London, UK)
P420	**Diabetes incidence trends and statin use among people living with HIV, 2016–2025** Golnaz Torkjazi, Tommaso Clemente, Nicolò Capra, Riccardo Lolatto, Emanuela Messina, Diana Canetti, Giovanni Festa, Dario Diana, Gabriele Loi, Silvia Nozza, Antonella Castagna, Vincenzo Spagnuolo (Milan, Italy)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: CV/metabolic including weight gain (continued)

P421	**Acceptability of body composition assessment methods in people living with HIV and/or chronic hepatitis B: findings from the BEHIVe study** Florence Bascombe, Catherine Johnson, Jennifer Curley, Ebunoluwa Taiwo, Christos Karathanasis, Laura Hennelly, Deirdre Sally, Jonathan Wells, Alun Hughes, Stuart Flanagan, Oliver Stirrup, Sarah L Pett, Richard Gilson, Alejandro Arenas-Pinto (London, UK)
P422	**After REPRIEVE: are we treating the right patients?** Beatrice Barda, Nadine Clea Natter, Lorenzo Magenta, Alessandra Bruno, Bruno Bertola, Enos Bernasconi, Marco Bongiovanni (Lugano, Switzerland)
P423	**Discordance among cardiovascular risk prediction tools in people living with HIV: a contemporary cohort study** Beatrice Barda, Enos Bernasconi, Bruno Bertola, Lorenzo Magenta, Alessandra Bruno, Marco Bongiovanni (Lugano, Switzerland)
P424	**Performance of the SCORE2 cardiovascular risk model in people living with HIV diagnosed prior to the modern ART era** Lieven Legius, Rosa Elias, Casper Rokx, Annelies Verbon, Berend van Welzen (Utrecht, Netherlands)
P425	**Efficacy, metabolic safety and patient satisfaction of DTG/3TC versus BIC/TAF/FTC in treatment-naïve men living with HIV: 24-week results from the randomized TEOTL trial** Paola Edith Padilla Noguera, Marco Antonio Cruz León, José Antonio Mata Marín, Ana Luz Cano Díaz, Gloria Elizabeth Salinas Velázquez, Emily Itzel Pecero García, Alan De León Aguilar, Alberto Chaparro Sánchez, Ericka Nelly Pompa Mera, Jesús Enrique Gaytán Martínez (Mexico City, Mexico)
P426	**One patient, two visits, five answers: longitudinal reclassification of cardiovascular risk in people with HIV** Beatrice Barda, Bruno Bertola, Enos Bernasconi, Lorenzo Magenta, Marco Bongiovanni (Lugano, Switzerland)
P427	**The cost of looking too young: missed opportunities for cardiovascular prevention in people with HIV** Beatrice Barda, Enos Bernasconi, Bruno Bertola, Lorenzo Magenta, Alessandra Bruno, Marco Bongiovanni (Lugano, Switzerland)
P428	**Factors associated with liver enzyme elevation in people living with HIV: metabolic, viral and endocrine co-factors outweigh antiretroviral exposure in the integrase inhibitor era** Natalia Laufer, Yazmin El Kozah, Jorge Gentile, Emilia Cohen, Marcelo Gañete, Gabriela Poblete, Graciela Guaragna, Florencia Ferrero, Raquel Zhumi, Fabricio Morales, Marina Grand (Buenos Aires, Argentina)
P429	**Efficacy, safety, metabolic impact and BMI evolution after switching to B/F/TAF in treatment-experienced people with HIV with obesity** Cinthia Lamaizon, Diego Cecchini, Macarena Roel, Gaston Copertari, Martin Brizuela, Brenda Bacelaar, Edgardo Bottaro, Isabel Cassetti (Buenos Aires, Argentina)
P430	**Accessibility of glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes and HIV infection** Alan Neiman, Ashley Wright, Brenda Martinez, Gerald Pierone Jr (Vero Beach, FL, USA)
P431	**Incidence of hypertension and associated factors in people with HIV initiating antiretroviral therapy with guideline-recommended regimens since 2009** Andrea De Vito, Marta Rava, Sergio Padilla, Julia Barrado Cuchillo, Marianela Ciudad Sañudo, Maria Saumoy, Cristina Hernández Gutiérrez, Marta Montero-Alonso, Jose Ignacio Bernardino, on behalf of CoRIS Cohort (Sassari, Italy)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: CV/metabolic including weight gain (continued)

P432	**Peripheral and non-compressible arterial diseases in HIV patients on dolutegravir versus atazanavir-based regimens: findings-in a multi-centre Nigerian study** Roland Ijimdiya Stephen, Jimmy Reyes, Li Ting Tan (Yola, Nigeria)
P433	**Modifying cardiovascular-kidney-metabolic syndrome trajectory in HIV: early evidence for GLP-1 receptor agonists** Alessandro Pecchi, Marianna Menozzi, Michela Belli, Cristina Mussini, Giovanni Guaraldi, Jovana Milic (Modena, Italy)
P434	**Efficacy and metabolic outcomes of DOR/TDF/3TC versus BIC/TAF/FTC in overweight, treatment-naïve people living with HIV: 24-week results from the COATL randomized trial** Ana Luz Cano Díaz, Mitzi Daniela Ramírez Ramírez, Paola Edith Padilla Noguera, José Antonio Mata Marín, Gloria Elizabeth Salinas Velázquez, Emily Pecero García, Alberto Chaparro Sánchez, Ericka Nelly Pompa Mera, Jesús Enrique Gaytán Martínez (Mexico City, Mexico)
P435	**Efficacy, safety and tolerability of switching to dolutegravir/lamivudine versus continuing INSTI-based triple therapy in virologically suppressed people living with HIV: 24-week results from the randomized TLACAELEL trial** Diego Armando Arteaga Badillo, José Antonio Mata Marín, Ana Luz Cano Díaz, Gloria Elizabeth Salinas Velázquez, Emily Itzel Pecero García, Jorge Fabian Pimentel González, Alberto Chaparro Sánchez, Ericka Nelly Pompa Mera, Sergio Santillán Arroyo, Jesús Enrique Gaytán Martínez (Mexico City, Mexico)
P436	**Abstract withdrawn**
P437	**Abstract withdrawn**
P438	**The influence of the T allele and CT+TT genotypes of rs2057482 on the presence of hypertension in people living with HIV** Nemanja Đorđević, Jovan Ranin, Ivana Gmizić, Marko Marković, Ivan Rajković, Jovana Ranin, Biljana Ljujić, Sofija Sekulić Marković, Ivana Lešnjak, Biljana Popovska Jovičić (Kragujevac, Serbia)
P439	**Dynamic changes in lipidome and cardiovascular risk factors after a stable switch to B/F/TAF in people with HIV** Biao Zhu, Zhikai Wan (Hangzhou, China)
P440	**Impact of antiretroviral class switching on cardiometabolic risk: data from the HIV-HEART-Aging cohort** Christoph Zacher, Laven Mavarani, Anja Stempel, Anja Potthoff, Martin Hower, Stefanie Sammet, Felix Maischack, Börge Schmidt, Stefan Esser, on behalf of HIV-HEART Aging Study Group (Essen, Germany)
P441	**Abstract withdrawn**

Co-morbidities and complications of disease and/or treatment: Malignancies (non-AIDS defining)

P442	**More than doubled risk of virus-related non-AIDS-defining cancers in people living with multidrug-resistant HIV: a matched multicohort analysis with data from the PRESTIGIO registry** Tommaso Clemente, Nicolò Capra, Letizia Oreni, Riccardo Lolatto, Giacomo Pozza, Simona Di Giambenedetto, Chiara Fornabaio, Elisa Fronti, Daniela Distefano, Maddalena Matone, Filippo Lagi, Adriana Cervo, Vincenzo Spagnuolo, Andrea Giacomelli, on behalf of PRESTIGIO Study Group (Milan, Italy)
P443	**Limited impact of late HPV vaccination on anal cytological outcomes in an aging cohort of people living with HIV** Davide Leoni, Elena Agostini, Angelica Buffa, Lolita Sasset, Samuele Gardin, Francesco Segala, Eleonora Vania, Anna Ferrari, Mazzitelli Maria, Cesare Ruffolo, Gaya Spolverato, Annamaria Cattelan (Padua, Italy)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: Malignancies (non-AIDS defining) (continued)

P444	**Two-thirds mortality within 5 years of lung cancer diagnosis among people with HIV of an Italian cohort** Gabriele Loi, Dario Diana, Nicolò Capra, Riccardo Lolatto, Vincenzo Spagnuolo, Angelo Roberto Raccagni, Tommaso Clemente, Elena Bruzzesi, Antonella Castagna, Silvia Nozza (Milan, Italy)
P445	**Burden of lung cancer among people with HIV in Italy compared to general population** Pierluca Piselli, Claudia Cimaglia, Alessandro Tavelli, Valentina Mazzotta, Arturo Montalbano, Alberto Zuppiroli, Adriana Cervo, Loredana Sarmati, Giuseppe Lapadula, Maria Vttoria Cossu, Antonella Castagna, Diego Serraino, Andrea Giacomelli, Antonella Cingolani, on behalf of ICONA Foundation Study Group (Rome, Italy)
P446	**Migration and HPV mucosal infection in people living with HIV: a prospective Spanish cohort study** Carmen Hidalgo-Tenorio, Cristina Rodriguez-Fernandez, Saioa Igartua, Mohamed Omar, Javier Lopez-Hidalgo, Javier Rodriguez, Mar Rivero, Coral Garcia, Inmaculada Calle (Granada, Spain)
P447	**Oral HPV prevalence and genotype concordance with anal HPV in HIV-positive MSM** Yoshiaki Kanno, Michiko Koga, Aiko Okazaki, Aya Ishizaka, Eisuke Adachi, Hiroshi Yotsuyanagi (Tokyo, Japan)

Co-morbidities and complications of disease and/or treatment: Neurological

P448	**Greater neurocognitive decline in older adults with well-controlled HIV infection compared with matched controls: the ANRS 0093s Aging HAND cohort study** Alain Makinson, Laure-Anne Gutierrez, Christian Geny, Eric Thouvenot, Valerie Andriantsoanirina, Manon Ollivier, Matteo Vassallo, Adrien Lemaignen, Charles Cazanave, Fabrice Bonnet, Marion Bourgey, Laurence Meyer, Olivia Zaegel, Thibault Mura (Montpellier, France)
P449	**Perceived sleep quality and domain-specific cognitive performance in people with HIV: unexpected findings from a neuropsychological cohort study** Giulia Del Duca, Ilaria Mastrorosa, Mattia Trunfio, Martina Maresca, Anna Clelia Brita, Roberta Gagliardini, Sandrine Valerie Ottou, Federico De Zottis, Rita Bellagamba, Giulia Micheli, Alessandro Giacinta, Valentina Mazzotta, Carmela Pinnetti (Rome, Italy)
P450	**Proteomic profiling of CSF and plasma in people with and without HIV** Merle Henderson, Luxsena Sukumaran, Caroline Sabin, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, Alex Everitt, John Tregoning, Sarah Fidler, Alan Winston (London, UK)
P451	**Domain-specific cognitive impairment in people with HIV on suppressive ART: a case-control study using MoCA** Domenico Velluto, Pasquale Troisi, Valentina Fortunato, Simona Madonia, Mirella Onofrio, Anna Maria Spera, Maria Teresa Pellecchia, Pasquale Pagliano (Salerno, Italy)
P452	**Neurosyphilis in the era of rising syphilis: CSF findings and clinical decision-making concordance in a real-world Portuguese cohort** Constança Azeredo, Lara Neto, Clara Bacelar, Sara Araújo, Maria João Gonçalves, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal)

Co-morbidities and complications of disease and/or treatment: Mental health disorders

P453	**Sleep disturbances in people living with HIV on stable antiretroviral therapy: a cross-sectional screening analysis** Vito Speciale, Daniele Pucci, Anna Carraro, Andrea Gasperin, Elker De Santis, Alessandro Di Nardo, Margherita De Masi, Daniela Di Trento, Giulia Mancarella, Valeria Filippi, Lorenzo Ansaldo, Cosmo Del Borgo, Serena Vita, Miriam Lichtner, Raffaella Marocco (Rome, Italy)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: Mental health disorders (continued)

P454	**Persistent cognitive depressive symptoms and their link to neurocognitive status in people with HIV: a longitudinal study** Giulia Del Duca, Alice Lener, Gianluca Frate, Martina Maresca, Valentina Mazzotta, Roberta Gagliardini, Ilaria Mastrorosa, Carmela Pinnetti, Andrea Antinori (Rome, Italy)
P455	**Major depressive episodes and psychiatric symptoms among HIV controllers compared with antiretroviral-treated people living with HIV** Marion Camard, Samia Hendou, Marie Bitu, Christelliah Mouanga, Faroudy Boufassa, Salomé Laurans, Jérôme Le Chenadec, Léo Plaçais, Véronique Avettand-Fenoël, Laurence Meyer, Christine Bourgeois, Emmanuelle Corruble, Olivier Lambotte, Romain Colle, Nicolas Noel (Le Kremlin-Bicêtre, France)
P456	**Psychological distress and housing instability as warning signs for early loss to follow-up among Latin American asylum seekers living with HIV** Samuel Manzano, Jorge Valencia, Guillermo Cuevas, Victor De la Fuente, Juan Torres Macho, Pablo Ryan (Madrid, Spain)
P457	**Hidden interface: HIV, severe mental illness and missed opportunities for care** Kevan Hilemichel, Sylviane Defres, Paul Hine (Liverpool, UK)
P458	**The accuracy of a multidimensional screening questionnaire for people with HIV: the MUSA study** Andrea Calcagno, Elisa Sala, Maria Cristina Poliseno, Maria Mazzitelli, Giordano Madeddu, Benedetto Maurizio Celesia, Giulia Marchetti, Laura Petroli, Maria Vittoria Cossu, Paola Cinque, Simona Di Giambenedetto, Mauro Giacomini, Rosaria Iardino, Daniela Vai, Luisa Brogonzoli (Novara, Italy)
P459	**No differential impact on 10-year cardiovascular risk despite lipid differences between BIC/FTC/TAF and DTG/3TC: a post-hoc analysis of the MIND trial (MIND-CORE study)** Sebastian Mendoza Ceacero, Diana Corona Mata, Claudia Ferreira-Tata, Angela Camacho, Antonio Rivero-Juarez, Antonio Rivero, Ignacio Pérez-Valero, on behalf of MIND Study Group (Cordoba, Spain)
P460	**Lost before discharge: psychiatric comorbidity and substance use associated with care disengagement in hospitalized young adults with perinatally acquired HIV in Argentina** Ana Martina de Prada, Javier Ricart, Laura Moreno Macias, Nicolas Nahoum, Cinthia Giomi, Matías Gastón Perez, Dana Mijalovsky, Graciana Cardenas, Matias Enzenhofer, Luis De Carolis, Natalia Vittar, Gustavo Bruni, María Florencia Villafañe Fioti, Emilse Vazquez, Sofia Bauer, Ruben Solari (Buenos Aires, Argentina)

Co-morbidities and complications of disease and/or treatment: Other

P461	**Immunomodulatory therapies in people living with HIV: changing patterns and infectious outcome from a real-world cohort** Anne-Claire Tournay, Emmanuelle Bontemps, Agnès Meybeck, Victoria Manda, François Raffi, Olivia Zaegel-Faucher, Manuel Etienne, Solene Patrat-Delon, Jean-Paul Viard, Pierre Delobel, Gewnael Le Moal, Olivier Robineau, Nathalie Viget, on behalf of MAIVIH Group (Tourcoing, France)
P462	**Renal impairment in children and young adults living with HIV in Europe and Thailand** Hannah Castro, John O'Rourke, Gabriela Toledo, Punnathorn Auaboonkanok, Katja Doerholt, Luminita Ene, Tessa Goetghebuer, Christian R Kahlert, Marisa Navarro, Lars Naver, Antoni Noguera-Julian, Magdalena Pluta, Wipaporn Natalie Songtaweesin, Vana Spoulou, Alla Volokha, Nadia Ahmed, Giorgia Dalla Valle, Luca Stona, Cassidy Henegar, Vani Vannappagari, Ana Puga, Charlotte Jackson, Ali Judd, Intira Jeannie Collins, Siobhan Crichton, on behalf of Epidemiology of Pregnancy and Paediatric Infections International Cohort Collaboration (EPPICC) (London, UK)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: Other (continued)

P463	**Efficacy and safety of darunavir/cobicistat plus lamivudine compared with darunavir/cobicistat plus tenofovir alafenamide/emtricitabine in virologically suppressed people living with HIV: less is more? A pilot study (TLALOC-2 trial)** Sandra Patricia Ramírez Eguía, José Antonio Mata Marín, Ana Luz Cano Díaz, Cruzwaldo Campos Cano, Emily Itzel Pecero García, Ericka Nelly Pompa Mera, Alberto Chaparro Sánchez, Jesús Enrique Gaytán Martínez (Mexico City, Mexico)
P464	**Persistent low-level viraemia is not associated with increased risk of serious clinical outcomes in the contemporary INSTI era: a time-updated analysis** Giovanni Festa, Riccardo Patanè, Nicolò Capra, Riccardo Lolatto, Gabriele Loi, Golnaz Torkjazi, Gaia Catalano, Hamid Hasson, Silvia Nozza, Antonella Castagna, Vincenzo Spagnuolo, Tommaso Clemente (Milan, Italy)
P465	**Long-term trends in serious non-AIDS events following ART initiation in the ICONA Cohort, 1997–2026** Adriana Cervo, Andrea Giacomelli, Alessandra Bandera, Rosaria Viglietti, Federica Casari, Sarah Dal Zoppo, Silvia Nozza, Andrea Gori, Antonella Cingolani, Enrico Girardi, Antonio Di Biagio, Antonella D'Arminio Monforte, Giovanni Guaraldi, Alessandro Cozzi Lepri, on behalf of ICONA Cohort Study Group (Modena, Italy)
P466	**Comparative performance of FRAX and FRAXPlus in predicting fracture risk and guiding osteoporosis management in people living with HIV** Giulia Moi, Dela Wordi, Andrea De Vito, Maria Mazzitelli, Mattia Giovanni Carlo Trunfio, Aparna Chaganti, Hana Soetanto, Alice Reeve, Shreeyaa Mishra, Jasmini Alagaratnam, Marta Boffito (London, UK)
P467	**Obstructive lung disease and HIV: a high-risk combination for major clinical outcomes** Andreas Ronit, Magnus Glindvad Ahlström, Josefine Amalie Loft, Andreas Dehlbæk Knudsen, Nicoline Arentoft, Thomas Benfield, Ken M Kunisaki, Børge Nordestgaard, Shoaib Afzal, Susanne Dam Nielsen (Copenhagen, Denmark)
P468	**10 years on: how has incorporation of health-related quality of life (HRQoL) in HIV research changed since the proposal of the '4th 90' target?** Garry Brough, Fernanda Duarte-Walker, Jose Gatell, Benjamin Young, Charles Hicks, Brent Allan, Erika Castellanos, Florence Riako Anam, Richard Harding, Nneka Nwokolo, Ian Jacob, Antonio Antunes, Felipe Rogatto, Ama Appiah, Chinyere Okoli (London, UK)
P469	**Abstract withdrawn**
P470	**Abstract withdrawn**
P471	**Causes of death among people living with HIV in Lesotho: a descriptive analysis of mortality data from the VITAL and SaDAPT studies** Fabian Raeber, Mokhebe Moleboheng, Malebanye Lerotholi, Lipontso Motaboli, Blaise Lukau, Palesa Mahlatsi, Felix Gerber, Nthuseng Bridgett Marake, Tarumbiswa Tapiwa, Irene Ayakaka, Nadine Tschumi, Niklaus Labhardt (Basel, Switzerland)
P472	**Exploring the associations of pre-existing metabolic comorbidities on changes in systemic inflammation indices in newly diagnosed people with HIV initiating antiretroviral therapy** Didem Çelik, Dicle Zeynep Aksu, Ayleen Mufudza, Sabri Atalay, Patrick W Mallon (Izmir, Türkiye)
P473	**Bone health in women living with HIV: unravelling distinct pathways of bone deterioration in a premenopausal cohort** Roser Navarro-Soler, María de Lagarde, David Rial-Crestelo, Juan Martín-Torres, Otilia Bisbal, Adriana Pinto-Martinez, Laura Bermejo Plaza, Mireia Santacreu-Guerrero, Fede Pulido, Rafael Rubio García (Madrid, Spain)

Scientific Posters

Co-morbidities and complications of disease and/or treatment: Other (continued)

P474	**Prevalence of osteoporosis among women living with HIV aged ≥ 50 years: a cross-sectional study** Luísa Lopes, Joana Marinho, Hugo Graça, Filipe Medeiros, Gonçalo Silva, Cristina Valente (Coimbra, Portugal)
P475	**Immune status and tenofovir exposure influence discordance between creatinine- and cystatin C-based eGFR equations in people living with HIV: a longitudinal analysis** Josip Begovac, Matea Rebrina, Ivana Javorić, Šime Zekan, Renata Laškaj, Mirjana Stupnišek (Zagreb, Croatia)
P476	**Similar prevalence of age-related comorbidities in people living with HIV and the general population in Israel: a multicentre matched cross-sectional study** Daniel Elbirt, Itzchak Levy, Liraz Olmer, Daniel Zibli, Anna Eisenberg, Ran Numa, Hila Elinav (Tel Hashomer, Israel)
P477	**Maintenance of HIV-RNA target not detected status after switching to BIC/FTC/TAF or DTG/3TC in anti-HBc-positive people with HIV** Arturo Ciccullo, Silvia Colaiuda, Francesca Lombardi, Andrea Carbone, Pierluigi Francesco Salvo, Giuseppe Cucinotta, Riccardo Serraino, Gianmaria Baldin, Carlo Torti, Simona Di Giambenedetto (L'Aquila, Italy)
P478	**Streamlining holistic care for people living with HIV: implementation of a digital referral tool to improve efficiency and patient outcomes** Katie Lamb, Dayan Vijeratnam, Sarah Oliver (Stevenage, UK)
P479	**Differential impact of tenofovir formulations on bone mineral density: long-term real-world evidence from a longitudinal HIV cohort** Giuseppe Lapadula, Laura Antolini, Francesca Iannuzzi, Alice Ranzani, Fiore Artelli, Viola Cogliandro, Nicola Squillace, Alessandro Soria, Maria Elena Locatelli, Paola Columpsi, Paolo Bonfanti (Milan, Italy)
P480	**Comparing hospital morbidity between people with HIV enrolled and unenrolled in the Swiss HIV Cohort Study** Marius Zeeb, Frederique Hovaguimian, Matthias Joos, Anders Boyd, Bernard Surial, Johannes Nemeth, Irene Abela, Silvio Brugger, Huldrych Günthard1, Roger Kouyos (Zurich, Switzerland)
P481	**Solid organ transplantation in people living with HIV: long-term outcomes from a Portuguese tertiary centre** Rita de Almeida Teixeira, Márcia Daniela Silva, Marcelo Pinto Alves, João Matos, Luís Marques Silva, Sofia Ferreira, Maria La Salete Martins, Ana Cipriano, Josefina Méndez (Porto, Portugal)
P482	**Layer-by-layer macular, peripapillary retinal nerve fibre layer thickness and minimum rim width changes in people living with HIV with undetectable viral load: an OCT-based study** Müge Toygar Deniz, Büşra Yılmaz Tuğan, Gözde Karaca, Nurşen Yüksel, Sıla Akhan (Kocaeli, Türkiye)
P483	**Occurrence of bacterial sexually transmitted infections in a Cork-based HIV pre-exposure prophylaxis (PrEP) clinic** Ciarán Hurley, Gabriella Rizzo (Cork, Ireland)

People living with HIV and mpox virus

P484	**MPXV-positive samples in Berlin 2022 to 2026: clade specific PCR, NGS sequencing and phylogenetic analyses** Merlin Lautner, Robert Ehret, Özlem Yildirim, Malik Prentice, Martin Obermeier (Berlin, Germany)
P485	**Clinical, epidemiological, vaccination-related and virological features of mpox clade Ib and contemporaneous clade IIb infections in Spain** Josep Riera, Laura Fuertes, Adrián Alfonso Álvarez, Adrià Mendoza, Patricia Álvarez-López, Irene Fuertes, Maria Carmen Ceballos Rodriguez, Elena Sendagorta, Ángel Rivero, Vicente Descalzo, Alba Catala, Alexy Inciarte, Ignacio Gadea Gironés, Almudena Gutiérrez-Arroyo, Susana Muñoz, Maider Arando, Esteban Martinez, José Luis Villanueva-Cañas, José Carlos Montañes, Miguel Julián Martínez, Sofia Pérez-del-Pulgar, Jose L Blanco, on behalf of MPOX1bESP Study Team (Barcelona, Spain)

Scientific Posters

People living with HIV and mpox virus (continued)	
P486	**Clinical and virological features of MPXV clade Ib versus clade IIb infection in the Italian MPOX-ICONA cohort** Valentina Mazzotta, Rebecca Jo Steiner, Paola Stolfi, Alessandro Tavelli, Angelo Roberto Raccagni, Maria Beatrice Valli, Francesco Caruso, Damiano Farinacci, Flavia Passini, Alessandro Mancon, Neva Braccialarghe, Nicola Clementi, Nicholas Brian Bana, Francesco Maria Fusco, Lorenzo Biasoli, Andrea Gori, Antonella Castagna, Fabrizio Maggi, Andrea Antinori, Licia Bordi, Davide Moschese, Silvia Nozza (Rome, Italy)
P487	**No changes in HIV RNA levels following mpox vaccination among people with HIV** Christian Hoffmann, Jens Forthmann, Carl Knud Schewe, Michael Sabranski, Axel Adam, Stefan Hansen, Stefan Fenske, Katharina Cron, Guido Schäfer (Hamburg, Germany)
P488	**Emerging mpox outbreak in Verona, Italy: incidence, clinical presentation and determinants of disease severity** Andrea Tamanini, Lorenza Lambertenghi, Maddalena Cordioli, Chiara Zanchi, Arianna Bellati, Anna Giulia Salvadori, Federica Salfa, Daria Pietroluongo, Evelina Tacconelli, Roberto Rossotti (Verona, Italy)
People living with HIV and sexually-transmitted diseases	
P489	**Tetracycline resistance and characteristics of Neisseria gonorrhoeae infection in MSM with and without doxycycline post-exposure prophylaxis** Cristina Gómez-Ayerbe, María López-Jódar, Salvador Martín-Cortés, Isabel A Pérez Hernández, Laura Mora, María Blanco, Rosario Palacios, Jesús Santos (Malaga, Spain)
P490	**Three years of real-world DoxyPEP use among PrEP users and people living with HIV: sustained effectiveness, safety and high adherence** Salvador Martín-Cortés, Cristina Gómez-Ayerbe, María López-Jodar, Andrea Prolo, Marina Villalobos, Andrés González-Jiménez, Jesús Santos, Rosario Palacios (Malaga, Spain)
P491	**Implementation of routine HPV screening in HIV care: high acceptability and clinical yield in a real-world cohort of people with HIV** Layla Pagnucco, Semela Resuli, Sofia Frattola, Raffaele Bruno, Roberto Gulminetti (Pavia, Italy)
P492	**When HIV prevention meets sexually transmitted Infections (STIs) resurgence: the paradox of treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP)** Barbara Bellocchi, Alessandro Franzò, Laura Todaro, Laura Pappalardo, Andrea Marino, Mariagiovanna Coco, Vittoria Moscatt, Federica Cosentino, Eugenia Pistarà, Serena Spampinato, Nunziatina Villari, Bruno Santi Cacopardo, Giuseppe Nunnari, Benedetto Maurizio Celesia (Catania, Italy)
P493	**Syphilis serological dynamics after penicillin versus doxycycline treatment among people living with HIV in Milan, Italy** Angelo Roberto Raccagni, Domenico Morace, Nicolò Capra, Riccardo Lolatto, Serena Rolla, Diana Canetti, Emanuela Messina, Vincenzo Spagnuolo, Tommaso Clemente, Antonella Castagna, Silvia Nozza (Milan, Italy)
P494	**Abstract withdrawn**
P495	**HPV awareness among people living with HIV** Aysegul Inci Sezen, Yusuf Emre Ozdemir, Esra Ensaroglu, Samiha Akkaya, Deniz Borcak, Sevtap Senoglu, Kadriye Kart Yasar (Istanbul, Türkiye)
People living with HIV and tuberculosis	
P496	**Abstract withdrawn**

Scientific Posters

People living with HIV and tuberculosis (continued)	
P497	**Prevalence of tuberculosis infection and associated risk factors among people with HIV and HIV-negative controls in Lithuania** Sarunas Raudonis, Birute Nakceriene, Rasa Girdziuniene, Aidas Kausas, Daiva Velyvyte, Aldona Eimutiene, Gertruda Arstikaitiene, Kotryna Vagoraite, Vilnele Lipnickiene, Jelena Kopeykiniene, Raimonda Matulionyte, on behalf of WEEPI Collaboration Group (Vilnius, Lithuania)
P498	**Abstract withdrawn**
P499	**Abstract withdrawn**
P500	**High burden of HIV and sexually transmitted coinfections among men admitted for tuberculosis at a referral infectious diseases hospital in Buenos Aires: seroprevalence and diagnostic yield of admission-based screening** Gabriela Poblete, Yasmin El Kozah, Nahuel Alberdi, Fernanda Sarralde, Karin Semorile, Guillermo María Onis, Natalia Pacífico (Buenos Aires, Argentina)
P501	**Early neutrophil-to-lymphocyte ratio dynamics at anti-tuberculosis treatment initiation as a bedside marker of subsequent clinical complications in hospitalized people with HIV/TB co-infection** Electra Stravodimou, Elli Kouriannidi, Christos Mamarelis, Vasiliki Rapti, Kalomira Athanasiou, Vasileios Maravitsas, Eleni Kakalou, Vissaria Sakka, Garyphallia Poulakou (Athens, Greece)
People living with HIV and viral hepatitis	
P502	**Establishing international expert consensus on hepatitis B assessment, monitoring and management in the context of HBV-inactive two-drug HIV therapy** Amy Paterson, Kyle Ring, Esteban Martinez, Jürgen Rockstroh, Alvaro Lopez Iñiguez, Chloe Orkin, on behalf of Hep B REACTIVATE 2DR Delphi Panel (London, UK)
P503	**International expert consensus on hepatitis B vaccination for people switching to HBV-inactive two-drug HIV therapy** Paterson Amy, Kyle Ring, Esteban Martinez, Jürgen Rockstroh, Alvaro López Iñiguez, Chloe Orkin, on behalf of Hep B REACTIVATE 2DR Delphi Panel (London, UK)
P504	**Safety of cabotegravir+rilpivirine long-acting regimen among people with HIV with previous HBV exposure: last update of the SCRIBE study** Nicholas Brian Bana, Camilla Muccini, Davide Paolo Bernasconi, Andrea Carbone, Simona Di Giambenedetto, Carlo Torti, Fiore Artelli, Giuseppe Lapadula, Paolo Bonfanti, Paola Vitiello, Clara Abeli, Eugenia Quiros-Roldan, Giorgio Tiecco, Laura Comi, Diego Ripamonti, Gaia Cologgi, Antonio Di Biagio, Massimo Puoti, Roberto Rossotti (Milan, Italy)
P505	**Incomplete HBV serological documentation could mask unrecognised immunity gaps in people living with HIV receiving tenofovir-sparing antiretroviral therapy** Natalia Laufer, Yazmin El Kozah, Jorge Gentile, Emilia Cohen, Marcelo Gañete, Gabriela Poblete, Graciela Guaragna, Florencia Ferrero, Raquel Zhumi, Fabricio Morales, Marina Grand (Buenos Aires, Argentina)
P506	**Cascade of care for chronic hepatitis B virus in people with HIV in Brazil and Mexico** Alvaro López Iñiguez, Yanink Caro Vega, Juan G Sierra Madero, Jessica Castilho, Fernanda Maruri, Sandra Wagner Cardoso, Hugo Perazzo, Estevão Portela Nunes, Valdilea Gonçalves Veloso, Brenda E Crabtree Ramirez (Mexico City, Mexico)
P507	**Persistent HBV viraemia despite ART: the critical role of HIV suppression in HIV/HBV co-infected individuals** Sara Nsibirwa, Katuku Aizire, Ponsiano Ocama, Gregory Kirk, on behalf of H2U Consortium (Kampala, Uganda)

Scientific Posters

People living with HIV and viral hepatitis (continued)	
P508	**Hepatitis C virus coinfection and reinfection after achieving sustained virological response among people living with HIV in northern Vietnam: a prospective multicentre cohort study** Junko Tanuma, Giang Van Tran, Truong Manh Nguyen, Thach Ngoc Pham, Masaya Sugiyama, on behalf of SATREPS HIV Cohort (Chiba, Japan)
P509	**Abstract withdrawn**
P510	**Glecaprevir/pibrentasvir versus sofosbuvir/velpatasvir for chronic hepatitis C in Latin America, including people living with HIV: the randomized ESGRIMA trial** Said López García, Ana Luz Cano Díaz, José Antonio Mata Marín, Emily Itzel Pecero García, Gloria Elizabeth Salinas Velázquez, Alberto Chaparro Sánchez, Ericka Nelly Pompa Mera, Jesús Enrique Gaytán Martínez (Mexico City, Mexico)
P511	**Liver fibrosis and steatosis burden in ageing people living with HIV: a real-world FibroScan-based assessment** Micaela Cueto-Marquez, Inês Cachapa-Vieira, Julia Lleixa-Martin, Marc Pedrosa-Aragon, Sonia Calzado-Isbert, Marta Navarro-Vilasaro, Maria del Carmen Navarro-Saez (Sabadell, Spain)
P512	**Linkage to HCV and HIV care among people with opioid use disorder in methadone and buprenorphine/naloxone clinics in Taiwan** Chien-Yu Cheng, Hui-ting Hsieh, Sheng-Chang Wang, Shu-Hsing Cheng (Taoyuan City, Taiwan)
People living with HIV and other infections	
P513	**Increased risk of laboratory-confirmed and severe influenza in a contemporary cohort of well-treated persons with HIV compared with matched population controls** Josefine Amalie Loft, Magnus Glindvad Ahlström, Andreas Dehlbæk Knudsen, Dina Leth Møller, Andreas Ronit, Thomas Benfield, Børge Nordestgaard, Shoaib Afzal, Susanne Dam Nielsen (Copenhagen, Denmark)
P514	**Prevalence of measles immunity and implementation of vaccination in London clinics** Suki Leung, Ruth Byrne, Nicolo Girometti, Lauren Bull, Michael Rayment (London, UK)
P515	**Archived HIV drug resistance mutations predict virological failure in virologically suppressed individuals on first-line antiretroviral therapy in Botswana** Dorcas Maruapula, Ontlametse Choga, Wonderful Choga, Natasha Mankge, Catherine Koofhethile, Joseph Makhema, Roger Shapiro, Shahin Lockman, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)
P516	**Abstract withdrawn**
P517	**Reactogenicity and immunogenicity of the recombinant HZ/su vaccine in people living with HIV** Valentina Sala, Roberta Rovito, Elena Zaninetta, Claudia Acampora, Marco Iannetta, Livia Benedetti, Matteo Augello, Valeria Bono, Camilla Tincati, Giulia Marchetti (Milan, Italy)
P518	**Abstract withdrawn**
P519	**The unexpected mimics of HIV serology: clinical predictors of false-positive HIV screening results in a 10-year retrospective cohort study** Yusuf Emre Ozdemir, Enes Topcu, Busra Nur Ozkan Ertay, Kubra Nur Bali Yurdakul, Samiha Akkaya, Damla Koklu, Zulal Zeynep Yurdakul, Deniz Borcak, Aysegul Inci Sezen, Sevtap Senoglu, Habip Gedik, Kadriye Kart Yasar (Istanbul, Türkiye)
P520	**Lived experiences and pathways to cryptococcal disease care and treatment: qualitative insights from people living with HIV-associated cryptococcal antigenemia in a clinical trial** Tshiamo M Mmotsa, Emily Prendergast Prendergast, Nellie Myburgh, David S Lawrence, Nelesh P Govender (Johannesburg, South Africa)

Scientific Posters

People living with HIV and other infections (continued)

P521	**Abstract withdrawn**
P522	**Acetate, a metabolite of gut commensal Blautia, specifically reverses CD8$^+$ T-cell exhaustion in HIV/SARS-CoV-2 co-infection** Xuan Yan, Xinyu Zhang, Yinzhong Shen (Shanghai, China)